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ABSTRACT
The overarching goal of this research is to explore the biological mechanisms of
aging and formulate novel therapeutic approaches to mitigate age-related impairments.
The presence and pervasiveness of ~24 hour (circadian) rhythms in molecular and
behavioral dynamics suggests that the mechanisms regulating these rhythms are
integral to biological aging and possibly amenable to therapeutic interventions. Based
on evidence presented in this dissertation, we conclude that the endocannabinoid
system is a mediator of both central and peripheral circadian physiology. Additionally,
the hormetic pharmacological properties of the synthetic cannabinoid CP55940 suggest
that bidirectional modulation of circadian rhythms via cannabinoids is possible.
Chapter 1 summarizes seminal work and recent advances in the fields of
biological aging, circadian rhythms, cannabinoid pharmacology, and the concept of
hormesis. The culmination of this chapter poses the central question: are exogenous
cannabinoids capable of bidirectionally restoring age-related changes in circadian
rhythms? Chapter 2 describes behavioral pharmacology studies wherein young and
aged mice were administered varying doses of CP55940 to determine how exogenous
cannabinoids affect locomotion, body temperature, and nociception. Data acquired from
these high-powered experiments demonstrate that CP55940 is significantly more potent
and efficacious in old mice, and that extremely low doses of this exogenous
cannabinoid elicit paradoxical locomotor stimulation in young mice.

ii

In Chapter 3 we quantified the age- and sex-specific characteristics of voluntary
wheel running (VWR) in mice housed under constant darkness - a model for age-related
circadian rhythm disruption. We then assessed the ability of CP55940 to alter the timing
of activity onset, offset, and total locomotion. Our results indicate that higher doses of
CP55940 given immediately after waking acutely suppress wheel running behavior but
lead to a rebound in activity later in the day. The final chapter summarizes these results
and discusses future studies which can expound upon this novel research. Collectively,
this work establishes experimental and analytical methods useful for investigating
cannabinoid pharmacology and evaluating circadian rhythm-restoring therapeutics in
aged rodents. Given the recent surge in cannabinoid use and the lack of preclinical
evidence of these compounds in elderly subjects, these results provide a critically
needed foundation for future experimental work.
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CHAPTER 1:
AGING, CIRCADIAN RHYTHMS, AND CANNABINOIDS
ABSTRACT
Numerous aspects of mammalian physiology exhibit cyclic daily patterns, known
as circadian rhythms. However, studies in aged humans and animals indicate that these
physiological rhythms are not consistent throughout the life span. The simultaneous
development of disrupted circadian rhythms and age-related impairments suggests a
shared mechanism which may be amenable to therapeutic intervention. Recently, the
endocannabinoid system has emerged as a complex signaling network which regulates
numerous aspects of circadian physiology relevant to the neurobiology of aging.
Agonists of cannabinoid receptor-1 (CB1) have consistently decrease neuronal activity,
core body temperature, locomotion, and cognitive function. Paradoxically, several lines
of evidence now suggest that very low doses of cannabinoids are beneficial in
advanced age. One potential explanation for this phenomenon is that these drugs
exhibit hormesis - a biphasic dose-response wherein low doses produce the opposite
effects of higher doses. Therefore, it is important to determine the dose-, age-, and
time-dependent effects of these substances on the regulation of circadian rhythms and
other processes dysregulated in aging. This review highlights three fields - biological
aging, circadian rhythms, and endocannabinoid signaling - to critically assess the
therapeutic potential of endocannabinoid modulation in aged individuals. If the hormetic
properties of exogenous cannabinoids are confirmed, we conclude that precise
1

administration of these compounds may bidirectionally entrain central and
peripheral circadian clocks and benefit multiple aspects of aging physiology.
BIOLOGICAL AGING
In humans, it is well accepted that the end of life is wrought with numerous
concomitant disease states which impose immense personal and social burden. As
such, the study of core biological processes involved in aging has become an
increasingly prominent topic. Interestingly, there is a clear dichotomy among individuals
regarding measures of age-related performance 1. This phenotypic heterogeneity is
particularly important when considering cognitive ability, since the deterioration of
mental functions can greatly influence a person’s quality of life. Though many aspects of
cognition decline with age, spatial orientation and speed of processing appear
particularly susceptible to age-related dysfunction 2. Physiologically, the loss of neuronal
synapses, chronic inflammation, oxidative stress, and impaired neurovascular coupling
all contribute to declining cognitive performance with age

3-5.

Fortunately, several

studies indicate age-related cognitive impairment can be partially prevented or delayed
using targeted pharmacological or hormonal interventions

6-10.

One of the earliest reported symptoms of aging is disturbed sleep

11,12.

Sleep/wake cycles are one example of the biologic phenomenon known as circadian
rhythms. Though sleep requirements change throughout the lifespan, sleep quality and
consistency are known to markedly deteriorate with age (Figure 1.1) 13. This is relevant
to cognitive decline since sleep is an integral factor in the consolidation of memory, and
age-related sleep disruptions are often concomitant with cognitive impairment and/or
neurodegenerative diseases 14-19. Despite the necessity of sleep for survival, defining
2

the physiological purpose of sleep has been exceedingly difficult. However, relatively
recent discovery of the glymphatic system and the sleep-dependent regulation of
metabolite clearance from the brain indicates that sleep is vital to the maintenance of
proteostasis in the central nervous system20. Since proteostatic dysfunction is common
in many pathologies of aging, disturbed sleep may play a causal role in age-related
cognitive disorders. Although it remains unclear how age-dependent changes in the
physiologic regulation of sleep are controlled, the maintenance of healthy sleep patterns
in advanced age seems undeniably important to cognitive function.
CIRCADIAN RHYTHMS AND AGING
Circadian rhythms are scale-invariant biological patterns that correlate to the
cyclic relationship of the Sun and Earth21,22. Extrinsic cues such as light and
environmental temperature are known as zeitgebers (time-givers) which entrain
organisms’ behaviors to particular times of day and improve evolutionary fitness (Figure
1.2)23,24. Though it has long been observed that animals behave in a manner inherently
tied to the time of day, only recently have the molecular and physiological underpinnings
of these processes been elucidated25-27. Importantly, changes in these clock genes are
attributed to both the process of aging and the pathogenesis of age-related diseases
11,28,29.

Seminal work in hamsters and mice revealed that when aged animals are
housed in complete darkness, their free-running (intrinsic) circadian rhythms of
locomotion are significantly different from younger animals 30-32. Additionally, studies of
molecular clocks indicate that both rhythm amplitude and regularity deteriorate with age
33.

More recent studies have confirmed these age-related changes in circadian rhythm
3

amplitude and period are exacerbated in the absence of environmental cues 34. Though
these findings suggest deteriorating rhythms can be masked or compensated by
environmental cues, aberrant sleep/wake cycles have also been observed in several
species of aged subjects under normal lighting conditions

13,17,19,35.

In addition to impaired sleep, the amplitude of circadian locomotor activity and
body temperature are known to decline in aging humans and rodents

36-38.

The

circadian range of rectal temperature in mice is ~2.0°C, which declines to 0.5-1.0°C in
advanced age; a similar reduction in range has been reported in humans 39-41. Daily
locomotion also goes down in mice, with average daily running wheel counts declining
by ~50% 42. Furthermore, sleep-dependent production of the pleiotropic humoral factor
Growth Hormone declines with age, and it is reported that these disruptions precede or
are comorbid with cognitive dysfunction 43,44. A recent study suggests that age-related
changes in the epigenetic regulation of the clock gene Per1 underlies some aspects of
cognitive decline 45. Whether circadian dysfunction is causal in age-related cognitive
decline remains to be known, however the striking overlap of these observations
warrants further investigation. Taken together, these observations suggest that both
molecular and behavioral circadian rhythms might be responsive to- and responsible
for- many aspects of biological aging.
Within the brain, the suprachiasmatic nuclei (SCN) of the mammalian
hypothalamus are believed to be the primary neural sites of circadian integration

46.

The

SCN as a whole, through unknown mechanisms, integrates the oscillatory rhythm of
each constituent neuron and collectively adopts a unified tone

27,47,48.

Neuronal

projections from the SCN transmit this coordinated rhythm to surrounding hypothalamic

4

and brainstem structures responsible for basic physiological functions such as the
sleep/wake cycle, locomotor activity, regulation of body temperature, and hormone
production 49,50. At the molecular level, cellular circadian clocks consist of transcriptiontranslation feedback loops which exhibit tightly coupled daily rhythms (Figure 1.3).
When exposed to a normal 24-hour light cycle, neurons of the SCN rhythmically
express these clock genes that oscillate with periods of roughly 24 hours

49,51.

Light,

temperature, food, and pharmaceuticals can all act as zeitgebers, which modulate
endogenous clock gene activity by extending or shortening the period of oscillation

52,53.

Such drugs, known as chronobiotics, influence circadian physiology by either directly
impinging on core clock molecules or altering entrainment systems. Therapeutically,
chronobiotics are used to shift or amplify endogenous circadian rhythms and reduce
dissonance with environmental conditions 54. Though circadian dysregulation is reported
with chronic or uncontrolled use of exogenous substances such as caffeine, cannabis,
and stimulant medications 55-58. Promising ongoing research suggests that chronobiotics
may be beneficial in cases of jet-lag, shift-work, and potentially aging, 59,60.
The SCN is often considered the primary regulator of mammalian circadian
rhythms, although cell-autonomous molecular feedback loops have been observed in
nearly all tissues throughout the body 61,62. In peripheral tissues, the period of each
cell’s rhythm is very near to 24 hours, although their exact rates are determined by body
temperature, humoral factors, and nutritional state

23,47,53,63-65.

Critically, in contrast to

the clock gene rhythms of peripheral tissues, neurons of the SCN appear resistant to
entrainment by body temperature 66,67. Since the SCN is directly responsible for the
rhythm of body temperature, this presents a potential mechanism through which the
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SCN can regulate clocks in peripheral tissues 62,68. Core body temperature - a vital
physiological output which exhibits circadian rhythmicity - declines with age, and older
subjects exhibit impaired thermogenesis 69-71. If the circadian rhythms of peripheral
tissues are functionally entrained by body temperature, then age-related impairments of
thermoregulatory capacity could explain why the rhythms of some peripheral tissues are
unable to be properly maintained. Furthermore, since neuronal activity in the SCN
determines central clock rhythms, and peripheral cellular clocks are entrained by
thermic signals, pharmacological interventions which influence both neuronal activity
and body temperature are of particular interest.
Declining circadian function with age is not associated with changes in overall
SCN volume, however several studies report altered physiological properties in this
brain region 72,73. In vivo electrophysiological recordings of the SCN show reduced
amplitude and “noisy” signals as animals age, suggesting that neuronal function is
compromised 32. Additionally, increases in reactive astrocytes have been observed in
the SCN of aged rodents 72,73. This is further emphasized by the concomitant agerelated reduction in neural excitability within one downstream region of the
hypothalamus innervated by the SCN, the subparaventricular zone. Mechanistically,
reductions in several forms of potassium conductance have been shown to contribute to
age-related alterations in SCN neural activity 74,75. More work is needed to understand
the molecular mechanisms that precipitate these functional changes in the SCN and to
determine their specific role age-related circadian dysfunction.
Even if targeting the SCN is not currently feasible, several studies demonstrate
pharmacological manipulation of the peripheral clock network is possible

6

61,76.

One of

the most profound regulators of lifespan across species is caloric intake, and evidence
in flies suggests that this effect on lifespan is mediated via peripheral circadian clock
gene expression 77. Pharmacologically, dexamethasone was shown to alter clock gene
expression in the liver, kidney, and heart via hormonal glucocorticoid signaling

78.

Peripheral circadian rhythms have also been modulated by drug-induced increases in
cAMP levels 61. These findings show that although some aged tissues are arrhythmic
they can still be pharmacologically induced to oscillate. Such reports are promising,
since they suggest the machinery governing clock gene expression in the periphery
remains intact even when the system is desynchronized. Targeting cAMP receptors is
particularly exciting, as G-protein coupled receptors (GPCRs) are often regulators of
cAMP. GPCRs are commonly successful drug targets, and over 35% of currently
approved drugs act on these receptors 79. Collectively, this implies that a large number
of proteins may be amenable to therapeutically regulating circadian signaling. Future
studies aimed at restoring circadian function within the SCN or preventing peripheral
dysregulation may simultaneously benefit multiple pathologies of aging.
THE ENDOCANNABINOID SYSTEM IN ADVANCED AGE
One potential target for the pharmacological manipulation of circadian rhythms in
advanced age is the endocannabinoid system

80.

Discovery of the endocannabinoid

system occurred when searching for the receptors responsible for the psychotropic
effects of plants from the genus Cannabis 81-83. Multiple cannabinoid receptors have
been identified in mammals, including the canonical CB1 and CB2 as well as morerecently identified receptors like GPR55 and GPR18

80,84-86.

These cannabinoid

receptors are GPCRs which exhibit distinct binding affinities for various endogenous
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and exogenous ligands 80,86,87. Radiographic localization of these receptors revealed
profound expression of CB1 in the brain and central nervous tissue, while CB2 is
primarily located in peripheral immune cells 88-90. The term cannabinoid refers to any
compound which binds to these receptors, while the term endocannabinoid specifically
refers to endogenously produced ligands 80. The endocannabinoid system consists of
these receptors and their endogenous ligands, which include Narachidonoylethanolamine (Anandamide) and 2-Arachidonoyl glycerol (2-AG) among
others 91,92. Numerous studies of the endocannabinoid system demonstrate that these
ligands and receptors collectively regulate sleep, hunger, body temperature, and
cognition – several of the circadian behaviors disrupted in advanced age

93-96.

As with many other physiological processes, the endocannabinoid system varies
markedly with age 97. There have been conflicting reports regarding age-related
changes of CB1 in the brain. Some reports in rodents suggest that CB1 mRNA
expression is reduced in advanced age

98,99,

while others indicate there is no change or

even region-specific increases in CB1 100-103. These discrepancies are also observed in
humans, with post-mortem analyses showing reductions in CB1 radiolabeling in some
studies, while newer PET scans of living individuals showing sex-specific increases in
CB1 reactivity within aged females 104-106. Despite the various reported changes in
expression, studies have shown a reduction in CB1-stimulated GTPγS functional activity
in rodents and humans 98,103,104. In addition to potential changes in receptor expression
and function, reductions in the endocannabinoid ligand 2-AG have been observed in
advanced age 107. Considering the importance of this brain region to learning, memory,
and pathologies of aging, it is likely that the changing endocannabinoid system impacts
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cognitive behaviors. In support of this idea, studies using CB1-deficient mice show that
reducing these signals leads to the development of unique age-related behavioral
disturbances earlier than wildtype mice 108. Curiously, young CB1-deficient mice
outperform wildtype controls in social and object recognition tasks as well as operant
learning paradigms, suggesting that the effects of the endocannabinoid system are
influenced by the developmental age of the animals

108-110.

Although the exact

mechanisms of these fluctuations are still under investigation, it appears that the
preservation of endocannabinoid system function is vital to the aging brain.
Given the extensive activity of endocannabinoids throughout the central nervous
system, there appears to be a substantial link between the endocannabinoid system
and those physiological processes subject to age-related dysfunction. Additional
evidence suggests that the endocannabinoid system plays a key role in circadian
physiology. Several circadian behaviors are intricately linked to endocannabinoid
signaling, namely: thermoregulation, nociception, locomotion, and food-intake 93-96.
Centrally, neurons of the SCN express CB1 and alter their rates of firing in the presence
of synthetic cannabinoid agonists and antagonists

111,112.

A recent primate study also

revealed a circadian rhythm of cannabinoid receptor transcription in both the central
nervous system and peripheral tissues 113. Moreover, cannabinoids are powerful
regulators of body temperature - indicating that these compounds indirectly entrain
peripheral cellular clocks. Taken together, these findings demonstrate a connection
between the behavioral impairments observed in advanced age, disrupted circadian
rhythms, and alterations in the endocannabinoid system.
CANNABINOID BEHAVIORAL PHARMACOLOGY

9

Although the endocannabinoid system is regulated by endogenous molecules
like 2-AG and anandamide, exogenous cannabinoids such as those found in Cannabis
are also known to modulate this system. Rigorous pharmacological study of Cannabis
(also known as Marijuana, Marihuana) has a long and complex history 114. Historical
records of Cannabis-use have been documented for millennia, but the structures and
potential functions of the chemicals synthesized within Cannabis are still being
elucidated 81,82,115,116. Two of the most-studied phytocannabinoids (plant-derived
cannabinoids), are Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), although
growing bodies of literature exist for cannabigerol (CBG), cannabivarin (CBV), and
many others 92. THC is considered to be the primary psychoactive compound in
Cannabis and is an agonist of both CB1 and CB2 116. The mechanism by which CBD
exerts its physiological effects is unknown and widely disputed, as the Ki for CB1 and
CB2 is over 100 fold lower than that of THC on these receptors

117.

Though most of the

focus is on phytocannabinoids like THC, it is important to also note that Cannabis
produces a wide variety of monoterpenoids and sesquiterpenoids - which may also act
directly on cannabinoid receptors 118,119. Extensive reviews of Cannabis,
phytocannabinoids 92, cannabinoid receptors 80, and endocannabinoid pharmacology
120,

have previously been published.
Human empirical and anecdotal evidence demonstrates that exogenous

cannabinoids profoundly impact cognition and physiology 114,115,121,122. However, studies
of phytocannabinoids are somewhat difficult to interpret given the extreme diversity of
compounds present in raw plant-matter or extracts. As such, knowledge of each
cannabinoid’s specific pharmacological profile is crucial to consider any potential
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therapeutic applications for these substances. Receptor-subtype-specific compounds
have been vital to delineating the shared and specific effects of CB1 and CB2 on
physiological functions 123,124. Many synthetic cannabinoids have been identified using
the Tetrad Assay – a battery of behavioral tasks for assessing CB1 function in rodents
80,125.

These tests measure locomotion, catalepsy, thermoregulation, and analgesia as

endpoints of CB1 receptor activity 125. Though the Tetrad Assay has proven useful as a
drug screening mechanism, its relatively limited scope does not permit full
characterization of an animal’s behavioral status, especially when one considers the
behaviors altered in advanced age. In addition to nociception, locomotion, and
thermoregulation, CB1 activity regulates learning and memory, sleep/wake activity,
food-intake, anxiety, attention, and cardiovascular function

126-133.

In both animals and humans, memory impairment following acute or chronic
administration of CB1 agonists has been repeatedly reported 134-138. However,
alternative studies indicate that these memory-impairing effects are dose- and agedependent 139-144. Recent evidence in rodents suggest that some these effects can be
partially blocked by co-administration with CBD, a finding which may explain why
anecdotes of whole-plant Cannabis-use often disagree with the receptor-specific effects
seen in animal studies 145,146. The diverse behavioral phenotypes elicited from
modulation of the endocannabinoid system emphasize the importance of understanding
this integral physiological system.
Despite the large volume of studies conducted on exogenously administered
cannabinoids, synthesis of this data is difficult due to inconsistent compositions of
phytocannabinoids, doses, and routes of administration (ROAs) 147-150. Additionally,
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there is a significant disparity between preclinical dosing regimens and those currently
accepted for human consumption. Regarding THC, many rodent experiments use
intraperitoneal doses ranging from 1mg/kg to 30mg/kg, however, current recreational
and clinical amounts for humans are closer to 0.15mg/kg orally 151-154. While the
pharmacokinetic profiles vary markedly between rodents and humans 155, several
studies now show that injections of THC can alter animal behavior and molecular
signaling at doses as low as 0.002mg/kg 140,156. Recent attempts have been made to
more adequately model the routes of administration used by humans 126,127,157-160. The
results of these studies indicate that cannabinoids administered orally have a delayed
onset and longer duration of action than when they are inhaled 127,158,161. These route of
administration-dependent effects are to be expected; however, preliminary evidence
suggests that chronic Cannabis-use may also alter the gut microbiome 162. Given that
recreational and medicinal cannabinoids are often administered orally, future studies of
microbiome-mediated cannabinoid metabolism are of particular importance. Taken
together, it is imperative that these discrepancies in dosing and route of administration
are carefully considered and discussed in future studies.
HORMESIS AND CANNABINOID CHRONOPHARMACOLOGY
There is little debate regarding the deleterious effects of cannabinoids in high
doses, however the reported effects of more modest amounts are somewhat conflicting.
High doses of THC (≥3mg/kg in rodents, ≥0.15mg/kg in humans) are consistently
reported to disrupt cognitive function in rodents and produce psychoactive effects in
humans 136,138,142,163-165. Despite the consistent inhibitory or soporific effects of
cannabinoids at higher doses, studies which have examined lower amounts often report
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stimulatory effects at the lowest doses tested 143,166-172. Though exogenous
cannabinoids are known to induce hypothermia and hypolocomotion, several
investigations have reported increased body temperature and locomotion following
treatment at low doses 171,173,174. A similar biphasic effect of THC on intracranial selfstimulation was reported in rats treated with 0.1 or 1.0mg/kg

167.

Based on this study,

the authors concluded that an acute intraperitoneal injection of 0.1mg/kg THC induced
reward-seeking behavior while the higher dose elicited anhedonia. Mechanistically, the
effects of higher doses appear to be mediated in-part by CB1 signaling in GABAergic
neurons 168. A growing body of literature now suggests that low doses (≤3mg/kg) of
THC and other synthetic cannabinoids may prevent certain aspects of age-related
cognitive decline in rodents 139,143,156,175.
Within the context of exogenously administered cannabinoids and cognition, the
hormetic dose-response of this compound may rectify these disparate reports 176.
Hormesis describes a biphasic dose-response where low amounts of a substance
produce opposite effects of higher doses

177.

Great efforts have been made in recent

years to catalog and characterize reports of dose-response experiments which cannot
be explained by traditional, linear models 178. Continued work in this field now suggests
that one explanation for this biphasic response is through preconditioning 179-181. This is
in line with work previously presented by Sarne et al. which indicates that exposure to
low doses of exogenous cannabinoids blunt the negative impacts of subsequent insults
180,182.

These findings have intriguing implications for the study of aging, since

preconditioning biological systems during critical developmental windows may bolster
resilience to age-related dysfunction 183,184.
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Interestingly, the hormetic dose-response of THC on body temperature has been
reported for many years (Figure 1.4A) 171,173,180. Additionally, exogenous cannabinoids
alter anxiety-related behaviors in dose-dependent, bidirectional manner - although the
nature of this relationship is poorly understood

185-188.

Early observations regarding the

time- and temperature-dependence of THC’s effects may also shed light on these
seemingly incongruent findings. A classic study by Ernest Abel revealed that the time of
day in which THC is administered drastically affects the physiological response, a
phenomenon now referred to as chronopharmacology 189. Similarly, an elegant study by
Pertwee and Tavendale in 1977 revealed that the ambient temperature markedly
altered rates of oxygen consumption and body temperature changes induced by THC
administration 190. Furthermore, sex-specific responses to cannabinoids may present a
confounding factor when interpreting these results, as previous reports have indicated
that doses of THC that impaired cognition in males actually improved measures in
females 191,192.
Given the current evidence, it is difficult to discern whether the cognitiveenhancing effects of low-dose cannabinoids are due to ‘true’ hormesis, age-dependent
changes in endocannabinoid function, or both. The work by Sarne and colleagues
demonstrates that exceptionally small amounts of THC (0.002mg/kg) are sufficient to
influence neurobiology. These studies reported that a single dose of 0.002mg/kg, IP
produced neuroprotection in young male mice and lasting cognitive enhancement in old
females 140,156,174,193. Critically, pilot studies at this dose were reported to increase body
temperature and stimulate locomotion - a finding which supports the hormetic
stimulatory response 180. While the evidence presented by Suliman also supports that
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the effects of cannabinoids are age-dependent, the data from this study indicate that
there is a ‘window’ in which cannabinoids may improve function 143. Although there are
not enough doses in these studies to clearly demonstrate hormesis, we feel that this
evidence is supportive nonetheless.
The range of doses studied by Sarne et al. indicate that doses which improve
cognitive performance in old animals (0.002mg/kg) cause impairments in young
animals, and the studies by Bilkei Gorzo et al. (3mg/kg THC) in old animals also support
this. These findings, and others, indicate a clear effect of aging on response to
exogenous cannabinoid administration. The possibility remains, however, that the
lowest dose of THC reported by Sarne et al. (0.0005mg/kg THC, IP) in young animals,
may still lie above the stimulatory hormetic range for this age group. This hypothesis is
supported by their biochemical studies which report the highest activation of P-ERK in
the cerebella of young animals at this dose (0.0005mg/kg) (Amal 2010).
To date, we are unaware of a modern study specifically designed to determine if
cannabinoids exhibit hormesis, and whether this hormetic dose-range is altered with
age. Even if preliminary evidence suggests there is cannabinoid hormesis in young
animals, it remains to be seen if this same hormetic curve persists with age or if the
stimulatory range might change. Though there are several potential mechanistic
explanations for these age-dependent effects, recent studies support a desensitization
of endocannabinoid machinery with age. Ultimately, additional studies testing multiple
doses in young and old animals are required to directly compare the hormetic range of
exogenous cannabinoids.
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Despite the importance of these pharmacological considerations across different
compounds and systems, hormesis and chronopharmacology remain understudied
components of many biomedical studies - particularly those in aged animals 194. These
two distinct properties have intriguing implications for the potential use of cannabinoids
as therapeutics. Namely, that it may be possible to attain opposing physiological effects
based solely on the dose- and time-of-administration. To this end, application of these
pharmacological properties to a highly dynamic and heterogenous condition such as
age-dependent circadian dysfunction, may provide a wide range of therapeutic potential
(Figure 1.4B).
CONCLUSIONS
Taken together, the findings discussed here suggest that altered circadian
rhythms are a potential biomarker of aging, and restoration or preservation of these
rhythms in aged individuals might benefit certain age-related pathologies. The
endocannabinoid system is a promising target in the treatment of age-related disease,
given the diverse physiological processes it regulates. Centrally, modulation of SCN
activity by cannabinoids supports their classification as a chronobiotics, and careful,
therapeutic application use of these compounds may serve to restore abnormal
behavioral rhythms in aged subjects. Moreover, the biphasic effects of cannabinoids on
body temperature may allow for the “tuning” of peripheral molecular clocks (Figure 1.5).
Many additional experiments are necessary to fully characterize the hormetic doseresponse of exogenous cannabinoids such as THC and examine their potential efficacy
in the amelioration of age-related circadian dysfunction. As societal opinions of ‘aging
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as a disease’ and ‘cannabinoids as medicine’ shift, further inquiry of these previously
intractable topics may prove greatly beneficial to human health.
FIGURES

Figure 1.1: The relationship between lifespan, healthspan, cognition, disease burden,
and survival.
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Figure 1.2: Environmental inputs and physiological outputs of mammalian circadian
rhythms.
Routine daily exposure to light entrains the SCN to a 24-hour period via the
retinohypothalamic tract. Neurons of the SCN rhythmically alter their rates of firing in
response to changing environmental conditions and humoral signals. Outputs from SCN
neurons drive central rhythms in hormone production, locomotor activity, feeding
behavior, and body temperature. Peripherally, cellular rhythms are entrained by the
daily oscillation of body temperature and food-intake. Since endocannabinoid activity is
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known to regulate SCN neurons, body temperature, and food-intake, evidence suggests
that the endocannabinoid system is a key component of physiological circadian
rhythms.
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Figure 1.3: Molecular components of cellular circadian rhythms.
The core circadian molecular loop consists of two proteins, Brain and muscle arnt-like 1
(BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK), which interact to
form a transcriptional activator complex that stimulates transcription of the Period and
Cryptochrome genes (PER1, PER2, CRY1, and CRY2). The Per and Cry proteins
accumulate in the cytoplasm throughout the day and ultimately bind to the
BMAL1:CLOCK complex. Sufficient binding of the PER:CRY complex to the
BMAL1:CLOCK complex prohibits transcription of PER and CRY mRNA. As protein
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levels of PER and CRY diminish, the BMAL1:CLOCK complex is allowed to stimulate
transcription once more.
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Figure 1.4: Hormesis and the chronobiotic potential of THC in aged subjects.
Panel A) Hormetic dose-response of THC on rectal temperature in rats. Data redrawn
from: Sofia, R.D., 1972. A paradoxical effect for 1-tetrahydrocannabinol on rectal
temperature in rats. Research communications in chemical pathology and
pharmacology, 4(2), pp.281-288.
Panel B) Declining amplitude and increasing lability of central and peripheral rhythms
with age may be amenable to therapeutics which simultaneously alter neuronal activity
in the SCN and body temperature. Using the chronopharmacological properties and
hormetic dose-response of THC, low-dose exposure may help to rescue dysfunctional
clocks in aging systems.
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Figure 1.5: Hypothetical model of cannabinoid hormesis in the restoration of age-related
circadian rhythm disruption.
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CHAPTER 2:
AGE-DEPENDENT HORMESIS-LIKE EFFECTS OF THE
SYNTHETIC CANNABINOID CP55940 IN C57BL/6 MICE.
ABSTRACT
Use of cannabis and cannabinoid-containing substances is increasing among
geriatric patients, despite relatively sparse preclinical evidence in aged models. To
better understand the effects of exogenous cannabinoids on aging male and females,
we compared the age- and dose-dependent physiological and behavioral effects of the
synthetic cannabinoid CP55940 in adult and aged C57BL/6 mice. Locomotion, body
temperature, thermal nociception, and fecal output were measured following CP55940
administration. Our findings indicate that CP55940 is more potent and efficacious in
older mice, evidenced by exaggerated antinociceptive and soporific responses when
compared to younger adult mice. Additionally, we report that low doses of CP55940
paradoxically stimulate locomotion in young mice, however this hormesis-like response
is not as evident in aged animals. These bidirectional effects appear to be mediated via
the endocannabinoid CB1 and CB2 receptors.
INTRODUCTION
Collectively, the canonical receptors (CB1 and CB2), endogenous ligands
(anandamide and 2-arachidonoylglycerol), biosynthetic regulators (N-acyl
phosphatidylethanolamine phospholipase D [NAPE-PLD] and diacylglycerol lipase-α
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[DAGLα]), and metabolizing enzymes (fatty acid amide hydrolase [FAAH] and
monoacylglycerol lipase [MGL]) of the endocannabinoid system are known to
dynamically regulate numerous aspects of mammalian physiology. Though extensive
work has been conducted on the behavioral and developmental effects of exogenous
cannabinoids early in life, substantially less is known regarding the physiological effects
of these substances in advanced age92,195. This lack of information, coupled with rapidly
shifting trends in cannabis- and cannabinoid-use worldwide puts elderly patients
particularly at-risk. Furthermore, emerging evidence suggests that the endocannabinoid
system may play a fundamental role in the biological processes of aging. This is
exemplified by transgenic mice that are genetically deficient in CB1, which exhibit
progeroid cognitive and physiological phenotypes108. However, pharmacological
manipulation of endocannabinoid signaling does not appear to produce consistent
effects across the lifespan. This is evidenced in studies where chronic infusion of the
phytocannabinoid Δ-9-tetrahydrocannabinol (THC) was shown to enhance cognition in
aged mice at doses which impair younger animals’ performance 139.
Cannabis and cannabinoid-containing substances have been used
therapeutically for millennia, but rigorous evaluation of their medical value is still
ongoing115. In preclinical rodent models, the effects of CB1-acting compounds are
traditionally measured using the “Tetrad Assay” - a battery of tests that measure
locomotion (open field), body temperature (rectal probe), catalepsy (ring-immobility),
and nociception (hot plate or tail withdrawal)196,197. The synthetic cannabinoid CP55940
is a well-documented, high-affinity CB1/CB2 mixed agonist which elicits the hallmark
phenotypes observed in these behavioral assays. Studies have demonstrated that the
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phenotypes produced by CP55940 are similar to those produced by high doses of the
phytocannabinoid THC - hypolocomotion, hypothermia, and antinociception - though
CP55940 is substantially more potent and efficacious than THC in these assays 198,199.
While there is consensus regarding the soporific, aversive, and antinociceptive
effects of CB1 agonists at high doses, several studies report contradictory stimulation of
locomotion, body temperature, and cognitive behaviors at low or ultralow
doses173,176,195,200. One explanation for these biphasic dose-responses is the biological
adaptive response known as hormesis183. Though hormesis, preconditioning, and
bidirectional dose-responses are widely evident in numerous biological systems,
systematic reporting of these low-dose effects is exceedingly difficult and often
overlooked. Such findings are critical, however, as the stimulatory hormesis-like effects
observed with low doses of cannabinoids in young animals may underlie the differential
cognitive effects reported in aged animals140,176,182. To date, we are unaware of a study
which specifically permits the comparison of young vs aged animals’ responses to low
doses of cannabinoids. To determine whether this biphasic response to cannabinoids is
age-dependent, we experimentally assessed the dose-dependent physiological and
behavioral effects of CP55940 at multiple doses in young and aged, male and female
mice.
RESULTS
Acclimation to Vehicle Injection and Baseline
In order to adequately capture potential biphasic behavioral and physiological
responses elicited by the synthetic CB1/CB2 agonist CP55940, we administered this
compound via intraperitoneal (IP) injection at the following weight-adjusted doses:
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0.001, 0.01, 0.1, 0.4, and 0.8mg/kg. Prior to treatment with CP55940, animals
underwent a 6-day acclimation period consisting of 3 days of handling and temperature
measurement, followed by 3 additional days of temperature recordings before and after
vehicle injection (1:1:18, EtOH:Kolliphor:Saline) (Figure 2.1). During the acclimation
period, baseline temperature was measured immediately before and 60 minutes after
injection using both a rectal probe and a non-contact infrared (IR) thermometer. During
acclimation recordings, both age groups showed a slight but consistent average
reduction in rectal and IR temperatures 60 minutes after injection of the vehicle solution
(Figure 2.2). Additionally, old mice weighed more while having lower baseline rectal
and skin/pelage temperatures than young mice (Figure 2.2).
Behavioral and Physiological Responses to CP55940
On the day of behavioral testing, male and female mice were injected with
varying doses of CP55940 or vehicle then assessed for locomotor, thermoregulatory, or
nociceptive responses. No sex-specific differences were observed throughout the study,
thus data from both males and females was combined. Activity measurements recorded
in the open field 30-60 minutes after injection indicate that treatment with CP55940
displays a significant Age:Dose interaction effect on total locomotion
(Locomotion~Age*Dose, H(5,351) = 11.451, p=0.043). Interestingly, young mice treated
with the lowest dose of CP55940 tested (0.001mg/kg) exhibit significantly increased
locomotion compared to age-matched vehicle-treated control animals (p<0.05, Fig.
2.3A). However, old animals administered this same dose did not significantly differ
from age-matched vehicle-treated controls. As expected, higher doses of CP55940
significantly reduced locomotion in both young and aged animals though this

27

suppression was evident in aged animals at a dose of 0.1mg/kg, which was not soporific
in young animals (Fig. 2.3A). In both age groups, doses of CP55940 ≥0.4mg/kg
induced severe catalepsy (Fig. 2.3A). Though no effect of Age was detected on fecal
output during the open field task (Feces~Age, H(1,297) = 1.57, p=0.210), young vehicletreated animals produced significantly more fecal pellets during the open field task than
old control animals (p=0.004). Additionally, at doses of CP55940 ≥0.01mg/kg fecal
output was significantly reduced in both age groups (Fig. 2.3B).
Immediately following the 60-minute temperature recordings, nociception was
quantified by placing each mouse onto a 52ºC heated plate and recording the latency to
lick its hind-paw or jump. Significant simple main effects of Dose (Latency~Dose,
H(5,353) = 149.41, p<0.001) and Age (Latency~Age, H(1,353) = 9.21, p=0.002) were
detected in this assay, though no interaction between these factors was observed (Fig.
2.3C). Among vehicle-treated animals, young mice were significantly quicker to respond
than older mice (p=0.005). The antinociceptive effects of CP55940 were highly
significant in both age-groups at doses of 0.4 and 0.8mg/kg, though aged animals were
significantly slower to respond than young animals at both of these doses. In later
cohorts of animals, nociception was also assessed via tail-immersion in a hot water bath
(46ºC). The results from these tests were similar to the hot-plate, although no main
effect of Age was detected (Fig. 2.3D). Intriguingly, a significant reduction in latency to
withdraw tail was observed in old animals treated with the intermediate dose of
0.01mg/kg (p=0.049). In agreement with the hot plate recordings, age groups showed
highly significant antinociception at doses of CP55940 ≥0.4mg/kg.
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Rectal and skin/pelage temperatures were measured 60 minutes post-injection
via rectal probe and infrared thermography. Both of these measures displayed a
significant main effect of Dose during behavioral testing (ΔRectal~Dose H(5,349) =
182.01, p<0.001 and ΔSkin ~Dose, H(5,340) = 146.06, p<0.001 ). In vehicle-treated
animals, rectal and skin/pelage temperatures were significantly elevated from baseline
in young and old mice (Fig. 2.3E-F). When compared to vehicle-injected animals, high
doses of CP55940 (0.4 and 0.8mg/kg, IP) significantly reduced rectal temperature in
both age groups. Importantly, this decline in rectal temperature was more pronounced in
aged mice, which exhibited reductions in rectal temperature at the dose of 0.1mg/kg
which had no effect in younger animals.
Responses to CP55940 and CB1 or CB2 Antagonism
To determine whether the biphasic effects of CP55940 could be accounted for by
activity at canonical cannabinoid receptors, we coadministered CP55940 with the CB1
or CB2 inverse agonists - AM251 or AM630, respectively. Based on previous literature,
doses of 3mg/kg AM251 or AM630 were administered to modulate CB1- and CB2mediated signaling and behavior201,202. Two doses of CP55940 shown to stimulate
locomotion in young males (0.001 and 0.01mg/kg,IP) were administered alone or in the
presence of AM251 or AM630; additionally, a high dose (0.8mg/kg) that significantly
reduces locomotion in both young and old animals was coadministered with
AM251(3mg/kg). AM251 alone significantly reduced locomotion (Fig. 2.4A) and
attenuated both the stimulatory and inhibitory effects of CP55940 on locomotion in
young males (Fig. 2.4A). In contrast, AM630 coadministration in young males
significantly attenuated the psychomotor stimulation elicited by CP55940 but did not
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block the reduction in fecal output produced by CP55940 at a dose of 0.01mg/kg (Fig.
2.5).
The CB1 inverse agonist AM251 also blocked the inhibitory effects of 0.01mg/kg
CP55940 on fecal output in young males (Fig. 2.4B). Fecal output was significantly
increased with coadministration of 0.8mg/kg CP55940 with AM251 compared to
0.8mg/kg CP55940 alone; although this was a partial rescue by AM251, as a significant
decrease from vehicle control was still observed with the coadministration of drugs (Fig
2.4B). Similar to the rescue of catalepsy, the antinociceptive and hypothermic effects of
0.8mg/kg CP55940 were abrogated by 3mg/kg AM251 (Fig. 2.4C-D), suggesting CB1
mediates many responses following high dose synthetic cannabinoid administration.
While aged animals did not show significant stimulatory locomotor effects with
low doses of CP55940, we verified that the mechanism responsible for the changes
observed with high doses of CP55940 was unchanged in advanced age.
Coadministration of AM251 significantly attenuated the hypolocomotor, antinociceptive,
and hypothermic effects of CP55940 in aged males (Fig. 2.4E-H). Similar to the effects
in young males, changes in fecal output were partially rescued by coadministration of
AM251 with CP55940 in aged males (Fig. 2.4F), although it is important to note that
AM251 alone significantly increased fecal output (Fig. 2.4F). 3mg/kg of AM251 also
reduced locomotor activity and significantly reduced body temperature in the aged mice
(Fig. 2.4E and H), similar to the changes seen with AM251 alone in the young males
(Fig. 2.4 A and D).
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Pharmacokinetics of CP55940 and Endocannabinoid Gene Expression in the Brain
To determine the mechanism for the enhanced potency of CP55940 seen in
aged animals, pharmacokinetic distribution of CP55940 in the blood and brain was
quantified following both 0.1 and 0.8mg/kg injections. Unfortunately, both of these
efficacious doses fell below the LC-MS/MS detection limits in these samples (data not
shown). Gene expression in brain tissue was also analyzed to determine whether the
expression of endocannabinoid receptors or their regulatory proteins was increased in
the aged animals that showed enhanced responses to CP55940. Significant reductions
in CB1 gene expression were observed in both cortical and hypothalamic tissue
samples from aged animals, (p=0.04 and 0.02, respectively) (Table 2.1). Fatty acid
amide hydrolase expression was also significantly reduced in the cortex of aged mice
(Table 2.1). No changes significant changes in CB2 were noted.
DISCUSSION:
Taken together, these findings reveal that the effects of CP55940 on
thermoregulation and behavior are highly age- and dose-dependent. Importantly,
CP55940 given to aged mice is significantly more efficacious than equivalent doses
administered to young mice, and the dose of 0.1mg/kg appears to be a key inflection
point in this differential response. In young mice, our data indicate that low (<0.01mg/kg,
IP) and high (>0.1mg/kg, IP) doses of CP55940 bidirectionally regulate measures of
locomotion, and these increases in total locomotion are not associated with thigmotactic
aversive behavior (Figure 2.6)203. However, under the present conditions we did not
detect significant CP55940-induced stimulation of locomotor activity in aged mice at any
dose of CP55940 tested. The distinct locomotor responses observed in both age groups
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at doses of 0.1mg/kg CP55940 indicate that continued characterization of this specific
dosing window may help to clarify these differing effects176,182.
In contrast to antinociceptive effects of CP55940 at doses ≥0.4mg/kg,
significantly enhanced nociception was observed in aged but not young mice tested
using the hot-water tail withdrawal task (Fig. 2.3D). As this task is less reliant on gross
locomotor activity than the hind-paw licking measured in the hot plate assay, the ability
to detect this effect highlights the importance of tasks with wide detection ranges and
sensitivity when studying hormesis. Additionally, the age-dependent responses seen in
these assays of nociception further highlight the importance of using multiple endpoints
when studying aged animals. Given the high prevalence of elderly patients seeking
cannabinoid-based therapeutics for chronic pain, additional studies in this model are
greatly needed.
During extensive vehicle acclimation recordings, both young and old mice
exhibited slight reductions in core-body and skin/pelage temperatures 60 minutes postinjection (Figure 2.2). However, on the day of behavioral testing, vehicle treated
animals consistently showed increases in rectal and IR temperatures (Fig. 2.3D and E).
One explanation for this differential response is that during behavioral testing, postinjection temperatures were taken immediately after animals completed open field
locomotor assessment. Therefore, it is possible that the hyperthermia observed
following vehicle-treatment in this context is confounded by locomotion in the open field.
Additionally, the high rectal temperatures recorded in young vehicle-treated mice
following open field testing may represent a ceiling-effect, precluding the replication of
previously-observed hyperthermia induced by low doses of cannabinoids 173. The
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effects of cannabinoids on thermoregulation may not be limited to brain-stem mediated
mechanisms and may also be influenced by peripheral vasodilation, as previously
reported204. Thus, we chose to measure skin temperature in addition to core body
temperature. A reduction in temperature of both measures was noted with high doses of
CP55940 in all groups tested.
Consistent with previous studies, no significant differences in locomotion were
observed with AM630 alone in this study (Figure 2.5). However, we were surprised that
the psychomotor stimulation with low doses of CP55940 was blocked by either AM251
or AM630. This suggests that both CB1 and CB2 mediate, at least in part, the hormeticlike response. Future studies comparing the effects of CB1 and CB2 antagonists using
cognitive assays where ultralow doses of cannabinoids have demonstrated protective
effects might further delineate whether the observed blockade of hormesis is unique to
locomotion or extends to other behaviors in rodents156.
It is not currently clear what the mechanism is which increases responsiveness to
this cannabinoid in the aged mice. In the present study, we observed significantly
decreased CB1 gene expression in aged mouse cortex and hypothalamus. This is
similar to previous research which demonstrated CB1 levels vary throughout the
lifespan, although these age-related changes appear to be region-specific99,103. A
reduction in receptor-expression by aged animals that show enhanced CB1-dependent
physiological phenotypes is perplexing, although a similar phenomenon was observed
in dopaminergic GPCRS. Following chronic receptor blockade, production of DA
receptor declines yet results in chemical “supersensitivity” 205. While CB1 expression
was decreased, there was also a significant reduction in the expression of FAAH1 in the
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aged cortex, suggesting potential elevations of endocannabinoid levels within our aged
mice. Future studies of cannabinoid receptor heterodimerization and biased agonism,
which have yet to be assessed in aged mammals, may also yield beneficial insight on
this matter. An alternative hypothesis is that cannabinoids may have increased access
to the central nervous system due to declining blood brain barrier function in aged
animals. During the course of this study we attempted to assess the pharmacokinetic
distribution of CP55940 in two independent cohorts of young and aged mice following
an injection of 0.1mg/kg and 0.8mg/kg. Despite the fact that these doses consistently
elicited behavioral phenotypes, this amount of CP55940 ultimately proved to be below
our detection limits in serum, liver, and whole-brain tissue samples.
Mechanistically, our studies with the CB1 and CB2 inverse agonists suggest that
the psychomotor, thermoregulatory, and antinociceptive effects of CP55940 at doses of
0.001 and 0.01mg/kg, IP are independently mediated by both receptors. Treatment with
AM251 alone produced simultaneous reductions in locomotion and rectal temperature,
while greatly increasing fecal output, suggesting that AM251 at a dose of 3mg/kg,IP is
aversive in young male mice. The notable observation that CP55940 at 0.01mg/kg
abrogates the antinociceptive effects of AM251 in young males (Fig. 2.4C) suggests
that this dose of CP55940 in combination with AM251 may restore tonic
endocannabinoid activity to baseline levels. The importance of maintaining tonic
endocannabinoid signaling has been discussed in detail previously, and the limited
effect of AM251 administration, by itself, suggests that the age-dependent responses
we observed may be due to elevated endocannabinoid tone206. As discussed, our aged
animals exhibited significant decreases in FAAH1, which could lead to increased
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anandamide levels in the aged cortex. It is possible that increased anandamide, or other
endocannabinoids, may contribute to the baseline difference in nociception between
age groups (Fig. 2.3C). Regardless, CB1 antagonism rescues many of the phenotypic
changes observed with high doses of CP55940 in both the young and old mice.
However, the failure of AM251 coadministration to rescue the reduction in fecal output
seen at the highest dose (0.8mg/kg,IP) of CP55940 tested (Fig. 2.4B) suggests a CB1independent mechanism, and may be due to interactions with the TRPV1 receptor as
recently reported 207.
We were surprised that the effects of CP55940 were not sex-specific, as aging
rodent studies are often marked by pronounced sex-dependent phenotypes208-211.
Moreover, studies of nociception and pain responses also commonly show sexdependent effects212,213, as well as known sex- and gender-specific differences in
cannabis abuse and physiological responses following cannabis consumption in
humans214,215. These studies often denote that such changes are driven in part by
differences in muscle mass and fat tissue distribution. In the current study, we did not
control for changes in body composition, estrous state, or the stage of reproductive
senescence within our young or aged cohorts but weight was consistently recorded and
all drugs were administered at weight-adjusted doses (Figure 2.2). Our data suggest
that the psychostimulatory effects observed at low doses and the robust inhibitory
effects seen at high doses are more strongly influenced by age than sex in mice.
The present study offers substantial evidence that the behavioral and
physiological effects of CP55940 are highly age-dependent, though several additional
considerations remain to be addressed. Specifically, the current experiments utilized a
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highly potent synthetic cannabinoid known to agonize both CB1 and CB2. Despite its
high affinity for these receptors, high doses of CP55940 modulate additional receptors
and influence physiological functions in cells that lack CB1 or CB2216. The expansive
endocannabinoidome presents numerous additional targets, such as the previously
mentioned TRPs or biosynthetic/metabolizing enzymes, which are also likely involved in
mediating the diverse effects of CP55940217. Additionally, though the consumption of
synthetic cannabinoids is increasing218, the use of cannabis and isolated
phytocannabinoids is far more common. Many phytocannabinoids exhibit unique
pharmacological profiles that target both canonical CB1 and CB2 endocannabinoid
receptors as well as other nonclassical endocannabinoid targets217. Accordingly,
expanded studies on the age-dependent effects of cannabis-derived compounds such
as THC and non-psychoactive constituents like CBD and terpenes are now greatly
needed.
Rising healthcare costs coupled with the increased availability of cannabinoidbased substances marketed as therapeutics have put elderly patients in a particularly
vulnerable position. Although aging phenotypes in humans and rodents are multifaceted
and exceedingly diverse, reduced physical activity, sleep disturbance, and chronic pain
are some of the most commonly reported conditions reported in advanced age. The
present study indicates that in mice, the synthetic cannabinoid CP55940 exhibits
bidirectional and behavior-specific effects that are greatly influenced by the age of the
subject. Therefore, additional studies are required to discern the mechanistic basis for
this increased responsiveness in aged rodents and to determine whether these agedependent effects are species and/or compound-specific. In the wake of rapidly shifting
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policies affecting access to cannabinoids worldwide, additional preclinical evidence in
aged models will be vital to anticipate potential effects these substances may have on
aging populations.
METHODS
Animals
All procedures were approved by the University of Mississippi Institutional Animal
Care and Use Committee (IACUC). Experimental cohorts consisted of two age groups:
2-4 months (young) and 21-24 months (old) of age. Experiments were performed on
male and female C57BL/6NHsd mice acquired from Envigo (Cat.#: 044) or C57BL/6
mice from the National Institutes of Aging Aged Rodent Colony. A priori power analysis
indicated that statistically significant differences based on a medium effect (Cohen’s f
>0.25) could be detected with group sizes n>=10. The total number of animals used for
this study is listed in Figure 2.8. All animals were housed in the AALAC-accredited
University of Mississippi Animal Facility and given access to food (Cat.#: 7001, Envigo
Teklad 4% Fat Rodent Diet) and tap-water ad libitum for the duration of experiments.
Mice were group-housed (4 mice/cage) in climate-controlled rooms (30-40% relative
humidity, 21-23°C) under a 12:12 ‘reverse’ light cycle (lights OFF at 8:00am and ON at
8pm). Upon arrival into the facility, animals were immediately group-housed in 75 in2
clear polycarbonate cages (Cat.#: AN76, Ancare) with 1/8” corn cob bedding and
environmental enrichment (Cotton Nestlets, Ancare, and Crink’l Nest, The Andersons
Lab Bedding) then allowed to acclimate to the facility for 7 days before experimentation.
Following this week of acclimation animals were weighed, fitted with a metal ear-tag
(Cat.#: INS1005-1LSZ, Kent Scientific) and randomized into balanced experimental
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treatment groups based on body weight. Mice were checked daily, and clean cages
were replaced every week. All experiments and procedures were performed under dim
red light (<1lux) during the animals’ active cycle.
Blinding
The experimenter was blinded to all treatment groups during drug-administration
and experimentation through the use of arbitrarily coded drug-containers.
Drugs, Dosing, and Administration
The synthetic cannabinoid CP55940 (Cat.#:0949, Tocris) was initially diluted in
100% ethanol (Cat.#:2701, Decon Labs) to a stock concentration of 10mg/mL and kept
at -20°C. The CB1 antagonist, AM251 (Cat.#:1117, Tocris) was initially diluted in 100%
ethanol (Cat.#:2701, Decon Labs) to a stock concentration of 10mg/mL and kept at 20°C. The CB2 antagonist, AM630 (Cat.#:1120, Tocris) was initially diluted in 66.6%
ethanol (Cat.#:2701, Decon Labs) and 33.3% Dimethyl sulfoxide (DMSO, Cat.#:
276855, Sigma-Aldrich) to a stock concentration of 6.66mg/mL and kept at -20°C. On
the day of each experiment, fresh vehicle solution was prepared by first dissolving
Kolliphor EL (formerly known as Cremophor EL, Cat.#: C5135-500G, Sigma Life
Science) in 100% ethanol, then adding sterile 0.9% HSP pH 7.4 saline (Cat.#:
00409488810, Hospira) in a ratio of (1:1:18). Experiments using AM251 or AM630 were
performed by pre-mixing either AM251 or AM630 with respective doses of CP55940
prior to injection. All drug mixtures were administered at a volume of 1mL/100g body
weight.
During testing, the animal’s temperature and weight were recorded then a body
weight-adjusted dose of vehicle or CP55940 was administered via intraperitoneal (IP)
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injection using a 1mL syringe (Cat.# 309602, Becton, Dickinson and Company[BD]) and
a 25 gauge needle (0.5 x 16mm, Cat.# 305122, BD).
Acclimation
On the day of behavioral testing, all animal cages were placed onto a plastic or
metal cart and relocated to the testing room where they were allowed to acclimate for 3
hours prior to testing. Throughout the acclimation and testing periods, the room
remained dark and white noise was continuously played at a volume of ~60db.
Body Weight
Body weight was measured at the start of every experimental procedure to
ensure accurate drug administration and as an endpoint for exclusion in the event that
an animal’s mass decreased >10% in a week. Animals were gently removed from their
cages by lightly gripping the base of their tail and placed into a lidless pipette-tip box on
top of the balance. Once the animal ceased moving the mass was recorded. In between
recordings, the pipette-tip box was wiped clean with ethanol, dried with a paper towel,
and the balance was tared.
Rectal and Pelage/Surface Temperature
Rectal temperature was measured using a Digi-Sense Advanced Precalibrated
Thermocouple Thermometer (Cat.#: EW-20250-91, Kent Scientific) which was
connected to a 1.9cm x 0.165cm rectal probe (Cat.#: RET-3, Kent Scientific). Before
measurement, the rectal probe was cleaned using 70% ethanol, dried, and lightly
lubricated with petroleum jelly. Animals were briefly immobilized on the top of a metal
cage lid, and then securely restrained by gripping the scruff (nape of the neck). After
confirming the animal’s identification/ear tag, the rectal probe was gently inserted 1.9cm
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into the animal’s rectum. Once a stable measurement was achieved (~3-5 seconds) the
temperature was recorded.
Skin/pelage temperature was measured via infrared thermography at the dorsal
pelvis using a FLIR Non-Contact Infrared Spot Thermal Camera (Cat.#: TG165, FLIR).
Emissivity was set to 0.85, as suggested previous research219. Immediately after
weighing, while the animal was standing still and upright in an empty pipette-tip box, the
thermal camera was held directly above the animal exactly 10cm away from the
animal’s skin. Once a stable measurement was achieved (~3-5 seconds) the
temperature was recorded.
Locomotion - Open Field
Locomotor activity was measured by placing a single mouse into a lidless clearplastic open field arena (41x41x38cm), which was surrounded by a 16x16 photobeam
array (Photobeam Activity System, San Diego Instruments) or recorded using a ceilingmounted camera. Locomotion in the X and Y directions were quantified using beam
breaks or software-based tracking (Ethovision XT-13, Noldus). During recording four
open field arenas were used simultaneously, and each arena was shielded on three
sides by 60cm black plastic dividers so that animals could not see each other. When
administered at high doses, the psychoactive effects of CP55940 are pronounced from
10-120 minutes. Thus, locomotor activity was measured continuously for 30 minutes,
beginning 30 minutes after drug or vehicle injection. Beam breaks in the X and Y
directions were sampled every 5 seconds for 30 minutes and then exported to
spreadsheets at the conclusion of testing. Peripheral locomotion was defined as any
locomotion which occurred in the outermost 50% of the open field arena. After removal
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from the open field, animals were briefly (1-5 minutes) placed into temporary cages
before testing on the hot plate.
Nociception - Hot Plate
Nociception was measured by placing a single mouse on top of a preheated
52°C thermal block (Cat.#: PE34, IITC Life Sciences), and recording the latency to
withdraw and/or lick their hind-paws. During testing, a hollow clear-plastic cylinder 25cm
in diameter by 35cm high was placed on top of the heated thermal block to prevent
animals from leaving the hot plate. Animals were placed in the cavity of the plastic
cylinder directly in contact with the hot plate and closely monitored for phenotypic
responses of nociception. Based on preliminary experiments, we concluded that the
latency to lick the hind paws was the most reliable indicator of nociception. Immediately
after licking their hind-paws, the timer was stopped and the animal was removed from
the hot plate and placed back into a temporary cage. If an animal failed to respond to
the thermal stimulus in 45 seconds, the timer was stopped and the animal was rapidly
removed from the hot plate to prevent tissue damage.
Nociception - Hot Water Tail Withdrawal
Several cohorts of male and female mice were also tested using a hot-water bath
preheated to 46°C. After testing on the hot plate, animals were allowed a 90s recovery
period, then gently scruffed by the nape of the neck and their tails were dipped 1/3 from
the tip into heated water. The latency to withdraw the tail was manually recorded using
a stopwatch.
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Gene Expression - qPCR
Cortical, hippocampal, and hypothalamic RNA was isolated using the RNA-easy
mini kit (Qiagen) and converted to cDNA using High-Capacity RNA-to-cDNA kit (Applied
Biosystems). RT-PCR was performed using TaqMan Universal PCR Master mix (Life
Technologies) and TaqMan validated primers (Mm01212171_s1 (Cnr1),
Mm02620087_s1 (Cnr2), Mm01187898_m1 (Cnrip1), Mm00515684_m1 (FAAH),
Mm03024075_m1 (HPRT), Mm99999915_g1 (GAPDH)) on the CFX Connect Real time
PCR detection system (Bio-Rad). Results were normalized to the housekeeping gene
HPRT. The experimenter was unaware of age group during testing and was unblinded
during delta-delta CT analysis.
Experimental Timeline
After ear-tagging and enrollment into treatment groups, a 6-day acclimation
period was begun. Initially, animals were acclimated for 3 days to handling, weighing,
and temperature measurement with the rectal probe and IR camera. Next, the animals
were acclimated for 3 days to all of the previous procedures, as well as IP injection of
vehicle (1:1:18, Ethanol:Kolliphor EL:Saline) and a follow-up 60m temperature recording
after the initial injection. Drug administration and behavioral experiments were
performed on the 7th day. In the event of repeated testing such as the AM251 and
AM630 studies (Figure 2.7), animals were left undisturbed for 7 days between rounds
of testing. Subsequent rounds of testing used only a 3-day acclimation period, wherein
the animals receive vehicle injections and 60m follow-up temperature recordings.
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Data Analysis, Statistics, and Exclusions
Data analysis was performed, collected, and analyzed using a combination of
Microsoft Excel (v2016, Microsoft), RStudio (v.1.1.456, RStudio Team), MATLAB
(r2019a, MathWorks), PAS (v2.0.3, San Diego Instruments), PAS Data Reporter
(v1.0.1.0, San Diego Instruments), Ethovision XT (v13, Noldus), and G*Power (v3.1, 220).
Prior to omnibus testing, all data for a given measurement was tested for outliers,
which was defined as those points that were greater or less than three interquartile
ranges above or below the 3rd and first interquartile ranges within a single treatment
group. After exclusion of these points, data from each measurement were assessed for
a normal distribution (Shapiro-Wilk test) and equal variance (Levene test). Since all
measures observed failed these tests, simple main effects and interactions were
assessed using the non-parametric Scheirer-Ray-Hare (S-R-H) test. A priori
significance was set at =0.05. Significant main-effects detected in S-R-H tests were
followed by additional post-hoc testing using Dunn’s many-to-one method, which is ideal
for comparing multiple dose-responses to vehicle/control treatments. The false
discovery rate was corrected for using the Benjamini, Hochberg, and Yekutieli method.
Additionally, notes regarding injection performance (by the experimenter) were kept
during all procedures and were the primary determinant for other exclusions. To
mitigate the effects of repeated testing, such as in the case of animals presented in
Figure 2, data in this figure have been normalized to the responses of vehicle-treated
animals that were tested at the same time.
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FIGURES

Figure 2.1: Experimental timeline.
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Figure 2.2: Baseline measures during vehicle acclimation.
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Figure 2.3: Effects of CP55940 on locomotion, thermoregulation, and nociception in
young-adult (4m) and old (22m) C57BL6 mice.
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CP55940 was administered via intraperitoneal injection at doses ranging from 0.001-0.8
mg/kg to young and old male and female mice. Individual data points for each testing
group are overlaid on Tukey-style boxplots. The lower and upper edges of each box
represent the first and third quartiles, respectively. The middle horizontal line in each
box depicts the median of that dose/age group. Sample sizes for every treatment group
and figure panel are listed in Figure 2.8. Statistical comparisons of Age, Dose, and
Age:Dose interactions were made using the non-parametric Scheirer-Ray-Hare test.
Significant omnibus results were followed by planned post-hoc contrasts of each dose
vs. vehicle-treated control groups using Dunn’s method. The false discovery rate was
corrected for using the Benjamini, Hochberg, and Yekutieli method. Within an age
group, significant differences (p<0.05) between a given dose and the vehicle response
(0 dose) are indicated using asterisks (*). Differences between age groups at a given
dose are indicated by pound signs (#).
Panels A-B) Total locomotion and fecal output during Open Field testing, 30-60 minutes
after injection of CP55940 or vehicle.
Panel C) Latency to exhibit nociceptive behavior when place on a 52ºC Hot Plate.
Panel D) Latency to withdraw the tail from 46ºC water.
Panel E) Change in rectal temperature 60m after injection of drug.
Panel F) Change in infrared recording of skin/pelage temperature 60m after injection of
drug.
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Figure 2.4: Behavioral and physiological effects of CP55940 co-administered with the
CB1 inverse agonist AM251 in young-adult (4m) and old (22m) male C57BL6 Mice.
Varying doses of CP55940 were administered alone or in a pre-mixed solution with
3mg/kg of AM251 Individual data points for each testing group are overlaid on Tukeystyle boxplots. The lower and upper edges of each box represent the first and third
quartiles, respectively. The middle horizontal line in each box depicts the median of that
dose/age group. Sample sizes for every treatment group and figure panel are listed in
Figure 2.8. Significant omnibus results were followed by planned post-hoc contrasts of
each dose vs. vehicle treated control-groups using Dunn’s method. The false discovery
rate was corrected for using the Benjamini, Hochberg, and Yekutieli method. Within an
age group, significant differences (p<0.05) between a given dose and the vehicle
treated response (0 dose) are indicated using asterisks (*). Differences between
CP55940 alone and CP55940+AM251 at a given dose are indicated by pound signs (#).
Panels A-D) Behavioral and physiological responses of young adult (4m) male mice.
Panels E-H) Responses of old (22m) male mice.
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Cortex
Young
Aged

n
6
5

CB1 ± SE
1.01 ± 0.06
0.81 ± 0.05
*p=0.04

CB2 ± SE
1.03 ± 0.09
0.82 ± 0.12
p=0.19

CRIP1 ± SE
1.07 ± 0.18
0.65 ± 0.08
p=0.08

FAAH1 ± SE
1.02 ± 0.10
0.59 ± 0.04
*p=0.004

CB1 ± SE
1.01± 0.06
0.60 ± 0.15
*p=0.02
*p ≤ 0.05 t-test, Young vs Aged

CB2 ± SE
1.4 ± 0.64
3.13 ± 1.12
p=0.19

CRIP1 ± SE
1.01 ± 0.06
1.11 ± 0.12
p=0.44

FAAH1 ± SE
1.00 ± 0.03
0.78 ± 0.11
p=0.07

Hypothalamus n
Young
6
Aged
5

Table 2.1: Quantitative-PCR analysis of gene-expression in regions of brain tissue from
young-adult (4m) and old (22m) male mice.
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Figure 2.5: Effects of CP55940 and AM630 coadministration in young males.
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Figure 2.6: Effects of CP55940 on peripheral locomotion in the open field.
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Figure 2.7: Animal cohorts and experiments
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Figure 2.8: Sample sizes.
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CHAPTER 3:
CANNABINOIDS AS CHRONOBIOTICS IN AGING MICE
ABSTRACT
A growing number of geriatric patients are seeking cannabinoid-based
substances for relief from age-related ailments such as poor sleep, low energy, and
chronic pain. Despite this increased demand for cannabinoid-based therapeutics,
preclinical evidence of these compounds’ efficacy safety in aged subjects is limited. The
current lack of preclinical studies in aged models and rapidly growing access to
cannabinoid-containing substances has placed elderly patients particularly at-risk.
Furthermore, a growing body of evidence suggests that the dose-response to
exogenous cannabinoids is bidirectional in young animals but not in aged subjects. A
critical limitation of previous studies is their relatively short duration, which precludes the
ability to assess multi-day effects of these compounds. To address these gaps in
knowledge, the present study examined the effects of age, sex, and treatment with
varying doses of the synthetic cannabinoid CP55940 on circadian rhythms of
locomotion in mice. Voluntary free wheel running behavior was monitored under normal
lighting (12:12, LD), constant darkness, and also with doses of CP55940 ranging from
0.001mg/kg to 0.1mg/kg, IP. Significant effects of both age, sex, and dose of CP55940,
as well as interactions among these variables were observed. Dose-dependent changes
in running behavior were observed on the day of cannabinoid treatment, as well as
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Age:Sex and Dose:Sex in the time of activity onset on the day after treatment.
Together, these data reinforce our previous findings that cannabinoids exert agedependent effects and establish a strong baseline for future studies aimed at testing
potential chronobiotics in young and aged animals.
INTRODUCTION:
The cyclic pattern of Earth’s rotation on its axis and revolution around the sun
has intimately shaped many aspects of biology. Though many of these biological
rhythms are now known to be regulated by the daily light cycle, those physiological
rhythms which persist in the absence of light are known as circadian rhythms.
Throughout much of the mammalian lifespan these ~24-hour physiological rhythms are
widely present and readily observable at numerous observational scales (molecular,
cellular, behavioral, etc.). At the biomolecular level, circadian rhythms of body
temperature dictate system enthalpy and, as a consequence, nearly all
thermodynamically reliant biochemical reactions. At the genetic level, the wellcharacterized circadian transcription and translation of ‘clock’ genes intricately regulates
numerous aspects of cellular physiology. In mammalian organs and tissues, consistent
rhythmic production of growth hormone, cortisol, and other endocrine modulators is vital
for proper growth, development, and function. Circadian patterns of behavioral activity
integrally shape organisms’ adaptation and evolutionary fitness within an ecosystem.
Collectively, these biologically pervasive rhythms are critical determinants of organisms’
survival.
The causal regulation of lifespan by circadian physiological rhythms is intuitive
but the quantification and assessment of this relationship remains elusive. Though the
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study of these two intricately related processes predates modern science, technical
limitations have historically hindered scientists to making only qualitative descriptions of
their relationship. Mus musculus (house mouse) is the most widely utilized mammalian
model in aging research, and our rich understanding of this species’ circadian genetic,
physiological, and behavioral characteristics is ideal for assessing pharmacological
interventions. This established wealth of knowledge is vitally important to intellectually
frame the observed outputs from these complex and dynamic biological systems.
Recent technological advances now permit the acquisition and analysis of such highdimensional (multivariate) data which may help to describe the organization and
behavior of many previously intractable biological processes.
Measures of circadian physiology such as locomotor activity, sleep/wakefulness,
and core body temperature are all regulated by rhythmic neuronal activity generated by
cells in the suprachiasmatic nucleus of the hypothalamus (SCN)37,38,74. The amplitude of
these neuronal rhythms, as well as measures of behavioral and physiological outputs,
are reduced in advanced age75. Older subjects also exhibit impaired thermogenesis
which may explain why peripheral tissues, whose rhythms are determined by changes
in body temperature, display impaired synchronization with age66,69. Voluntary wheel
running (VWR), also known as spontaneous wheel running, is a well-established and
commonly reported measure of circadian locomotion in rodents21,30. When presented
with a running wheel, mice, rats, hamsters, and many other species of animals will
voluntarily run. In the laboratory setting, quantification of this activity reveals circadian
patterns which correlate to the animal’s sleep/wake cycle and can be used as a
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surrogate measurement for the intrinsic physiological processes now known to regulate
this behavior.
Therapeutically, drugs which influence circadian physiology are known as
chronobiotics (e.g. melatonin) and are used to shift or amplify endogenous circadian
rhythms and reduce dissonance with environmental conditions54. Both cannabinoid
receptor-1 (CB1) transcript and protein are present in the SCN, and direct application of
CB1 agonists alters the activity of these neurons. Given that sleep, body temperature,
locomotion, and other daily physiological rhythms are primarily generated by neuronal
activity in the suprachiasmatic nucleus, the presence of CB1 in these cells supports a
role for endocannabinoids in circadian rhythm regulation 112. Although preclinical and
human studies overwhelmingly report deleterious outcomes on cognitive performance
resulting from chronic high levels of cannabinoid-exposure early in life, several studies
indicate that these memory-impairing effects are dose-, age-, and sexdependent97,128,134,141,143,191,192.
CB1 agonists induce profound hypothermia and hypolocomotion at high doses in
preclinical rodent models, though several investigations have reported increased body
temperature and locomotion following treatment with much lower doses171,173,174. One
explanation for these disparate reports is that exogenous cannabinoids exhibit
hormesis; that is, low-doses of these compounds produce the opposite effects of highdoses. Mechanistically, the effects of higher doses appear to be mediated in-part by
CB1 signaling in GABAergic neurons, although this may not be the case for all
behaviors168. Since neuronal activity in the SCN determines central clock rhythms, and
peripheral cellular clocks are entrained by thermic signals, pharmacological
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interventions like cannabinoids may provide a wide range of therapeutic potential due to
their known influence on both neuronal activity and body temperature.
CP55940 bidirectionally modulates locomotion in mice (Chapter 2), however it
remains to be shown whether this compound can dose-dependently increase and
decrease VWR in mice. Additionally, previous studies of hyper- and hypo-locomotion
caused by synthetic cannabinoid agonists have been limited to short periods of time (<6
hours) immediately following drug exposure. To address this, the current study permits
the measurement of potentially multi-day behavioral effects resulting from a single
exposure to CP55940.
The fundamental hypothesis of this work is that circadian locomotion is a
macroscopic readout of intrinsic physiological function, and the pharmacologic
restoration of age-dependent changes of behavioral endpoints will correspondingly
mitigate the onset of age-related pathology. To this end, the goal of this study was to
explore a computationally-intense, quantitative approach to extract defined features that
characterize circadian locomotion across the lifespan in mice. Our initial goal was to
establish baseline measures of circadian locomotion by quantifying the age- and sexdependent characteristics of rhythmic VWR in C57BL6 mice under normal lighting
conditions and in constant darkness. Once these age- and sex- specific rhythms were
quantified, separate cohorts of mice were administered varying doses of the synthetic
cannabinoid CP55940, and the efficacy of this compound to influence measures of
circadian locomotion was assessed.
RESULTS:
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In order to test the hypothesis that cannabinoid agonists can modulate behavioral
rhythms of spontaneous wheel running, we first sought to quantify baseline locomotor
rhythms in young and aged male and female mice housed under normal (12:12, LD)
lighting and constant darkness (00:24, DD). The use of these two lighting conditions
was used to understand potential baseline differences among the age and sex groups
which may only be present in the absence of light entrainment. Light is a profound
regulator of mammalian locomotor rhythms; therefore, the presence of light can mask
intrinsic ‘free-running’ locomotor rhythms34. Mice were group housed prior to wheel
running and kept in a dedicated room with ‘reverse’ lighting - 12 hours of darkness,
beginning at 8am (ZT hour 12), followed by 12 hours of light beginning at 8pm (ZT hour
0). On the first day of testing during the animals’ active (dark) cycle, mice of a single
age/sex group (n=11-12) were weighed then individually housed in cages containing
remotely monitored running wheels. Mice were then left undisturbed for 7 days under
normal lighting conditions (Fig. 3.1A) and wheel rotations per minute were recorded.
At the end of 7 complete days, a customized light-proof breathable cage-rack
cover was placed over all cages. Mice were then left undisturbed, in constant darkness,
for an additional seven days of recording. Running wheel activity of each age and sex
group during normal lighting and constant darkness has been summarized in Figure
3.2. Under normal lighting conditions, all mice exhibited a clear entrainment to the lights,
as evidenced by their consistent waking time shortly after lights-off (Zeitgeber Time [ZT
Minute 720, ZT Hour 12]) and periods of activity very near to 24 hours (Fig. 3.2E-H).
During normal (12:12) lighting, there were no significant differences between the LombScargle computed periods of any age/sex groups. However, under constant darkness a
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significant interaction of Age:Sex was detected (2-way ANOVA, DD_Period ~ Age *
Sex, Age:Sex, p<0.001). Interestingly, post hoc analysis revealed that young males’
(YM) circadian periods were not different from those of old males (OM), but the periods
of YM were significantly shorter than those of young females (p<0.001). Additionally, the
circadian periods of young females (YF) were significantly longer than those of old
females (OF, p<0.001); though no sex specific differences were observed in aged male
and female circadian periods.
In addition to quantifying the period, we also quantified total locomotion as well
as the timing of activity onset and offset. Quantification of this baseline activity revealed
that YM and YF mice exhibited sustained activity while the lights remained off, though
male mice at both age groups had substantially lower RPMs than age-matched females.
OM mice exhibited the lowest average daily activity, totaling only 11,925(± 1,301) total
rotations compared to 42,7681(± 1,259) total rotations by YF under normal lighting
conditions (Fig. 3.3J). YM averaged more daily activity than OM (p<0.001) under
normal lighting and in constant darkness (Fig. 3.3J-I, p<0.001). Similarly, YF averaged
more daily wheel rotations than OF in normal lighting as well as constant darkness (Fig.
3.3J-I, p<001). All age groups averaged more activity during constant darkness;
however, the change in activity from normal lighting to constant darkness was
significantly higher in old females (OF) compared to OM (Fig. 3.3L, p<0.01).
The timing of activity onset and offset were defined as the first 10-minute period
of average wheel running that exceeded 20% of that age/sex group’s daily maximum.
Using this threshold, we observed that under normal lighting conditions YM, YF, and OF
all had prompt activity onset following lights off, but OM were significantly slower to
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reach the activity onset threshold (Fig. 3.3A). Under constant darkness, we observed a
significant Age:Sex interaction, wherein YM, OM, and OF mice all began to advance
their circadian phases and began running earlier in the day than when housed under
normal lighting (2-way ANOVA, Age:Sex, p=0.001). In contrast, YF mice remained
remarkably consistent following the transition from normal lighting to constant darkness
and were significantly different than young males (p<0.01, Fig. 3.3C). Substantially
greater variability across all groups was seen in the timing of activity offset, even under
normal lighting conditions (mean onset LD [730±6.0 minutes], mean offset DD
[1286±24.8 minutes], Fig. 3.3D). Young male and female mice had significantly later
offsets of activity than older mice during normal lighting (Fig. 3.3D). Nevertheless, a
profound effect of age was observed when we quantified the timing of activity offset
during LD and DD, with older animals ceasing activity significantly earlier than young
mice (p<0.001, Fig. 3.3D-E). On average, YF had the latest activity offsets and were
significantly later to stop activity in DD than young males (p<0.05, Fig. 3.3E).
To account for the varying shifts in both onset and offset, we quantified overall
duration of activity by subtracting the time of activity onset from the time of activity onset
(Fig. 3.3G). Under both normal lighting and constant darkness, YM and YF groups had
longer durations of activity than OM and OF groups (p<0.01) though there were no
significant differences between the sexes in either age group (Fig. 3.3G-H). Despite
this, the change in duration of activity from normal lighting to constant darkness was
greater in young mice compared to old mice. To our surprise, substantial heterogeneity
in onset and offset timing was observed among animals of the same age/sex when
transitioning from LD to DD. Table 3.1 qualitatively categorizes these differences, based
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on whether individual animals advanced or delayed their respective time of onset or
offset by ±15 minutes. In DD, the majority of YM and OM advanced their phases. In
contrast, while all of the OF mice were phase advanced, YF tended to onset and offset
activity later (Fisher’s Exact Test, YF:OF, p= 0.006, Table 3.1).
After completing the baseline recordings, cohorts of naïve young and old male
and female mice were used to assess the ability of the synthetic cannabinoid CP55940
to alter locomotor rhythms (Fig. 3.1B). In these experiments, mice were exclusively
housed under normal lighting (12:12, LD) and allowed to acclimate to single-housing
and wheel-running for 14 days prior to drug treatment. Beginning 30-60 minutes after
lights off on the 15th day (8:30-9:00am, ZT hour 12.5-13), animals were administered a
single intraperitoneal injection of either vehicle (1:1:18, ethanol:Kolliphor:saline) or one
of three doses of the synthetic CB1/CB2 agonist, CP55940 (0.001mg/kg [Low],
0.01mg/kg [Med], 0.1mg/kg [High]). Following injections of the synthetic CB1/CB2
agonist , animals were returned to their cages and allowed to freely run for 72 hours
before receiving the next of the 3 remaining doses. Ordering of the dose-administrations
was randomized based on a Latin-square experimental design.
3D and 2D representations of each age/sex/dose group’s average activity on the
days before, during, and after each injection are show in Figures 3.4, 3.5, and 3.6. In
Figures 3.4 and 3.5, “Day of Running 1” was the day before drug injection, “Day of
Running 2” is the day of drug administration, and “Day of Running 3” is the day after
drug injection. Obvious depressions in locomotor activity can be visually observed with
these 3D representations when the mice are treated with 0.1mg/kg CP55940.
Additionally, the middle row of Figure 3.6 clearly depicts the sustained locomotor
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effects of CP55940 at different doses on the day of injection. Since most behavioral
assays of cannabinoid-mediated effects do not assess behavioral changes beyond 1-2
hours following drug administration, we quantified CP55940-induced changes in
locomotion at three different time scales: 1-hour post injection, 1-6 hours post injection,
and 6-12 hours post injection (Figure 3.7).
Figure 3.7A summarizes total voluntary wheel running during the hour
immediately following drug administration. In this short time-period, we observed
significant simple main effects of Dose, Age, and Sex (p=0.023, p<0.001, p=0.003,
respectively). When compared to vehicle-treated control mice, the highest dose of
CP55940 tested (0.1mg/kg, IP) uniquely suppressed wheel-running in the aged mice
(Fig. 3.7A). However, when activity throughout the first 6 hours after injection were
summed, we also observed significant hypolocomotion in YM as well as both sexes of
older mice (Fig. 3.7B). We also examined wheel running from 6-12 hours post injection
to determine whether the hypolocomotion experienced early in the animals’ subjective
day would be compensated for by additional running in the subjective evening. We
observed significant main effects of Age, Sex, and Dose on wheel counts from this time
frame (Fig. 3.7C). Post hoc analysis of the 3-way ANOVA indicated that the high dose
of CP55940 (0.1mg/kg) significantly increased wheel running 6-12 hours post injection
across both ages and sexes compared to vehicle treated mice, though no significant
interactions between Age, Sex, and Dose were detected (p=0.009, Fig. 3.7C). This
suggests that while 0.1mg/kg CP55940 leads to hypolocomotion in the first few hours
following administration, the animals compensate with increased activity later in the day.
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Indeed, when the entire 24-hour day was analyzed, no differences in total wheel
rotations were observed.
To test whether the short-term reductions in locomotion immediately following
CP55940 administration were compensated by higher levels of total running during the
animals’ subjective evening or if this hypolocomotion persisted to the next day, we
quantified the time of activity offset on the day of injection and the animals’ time of
activity onset on the following morning (Fig. 3.8). Significant main effects of Age and
Sex were detected in both the time of activity offset on injection day, revealing that
young mice are active later than old mice and male mice are active later than female
mice (p<0.01, p<0.001, Fig. 3.8A). However, when we compared the time of activity
offset on injection day to the time of offset on the prior day, this significance was not
dependent on Age, only Sex (p<0.05, Fig. 3.8B). Similarly, overall running duration on
the day of injection was longer in young mice, and male mice had longer running
durations than females (p<0.001, p<0.01, Fig. 3.8C) Again, when running duration was
compared to activity on the day before injection, only a significant effect of Sex was
detected (p<0.05, Fig. 3.8D).
Finally, we wanted to know whether the effects of CP55940 administered during
the animals’ subjective morning had measurable effects on the following morning’s time
of activity onset. We observed a significant effect of Sex on the time of activity onset the
day after injection, with female mice becoming active later than male mice (p<0.01, Fig.
3.8E). When we compared the timing of activity onset to the day before injection, we
observed significant Age:Sex and Dose:Sex interaction (p=0.003, p=0.042, Fig. 3.8F).
OM had the largest shift in activity onset compared to the day before injection,
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becoming active significantly earlier than all other age and sex groups (p<0.001, Fig.
3.8F). However, the medium dose of CP55940 (0.01mg/kg, IP) significantly delayed
activity onset in both young and old males.
DISCUSSION:
The experiments described here rigorously assessed the age-, sex-, and dosedependent effects the synthetic cannabinoid CP55940 on voluntary wheel running in
mice. While much work has focused on understanding circadian biology and its
influence on aging pathologies, few studies specifically seek to pharmacologically
rescue these age- and sex- specific changes using wheel running as a read-out. As
biological aging is marked by pronounced sex-specific phenotypes, the quantification of
baseline age- and sex-differences in voluntary wheel running was a critical first step to
determine the efficacy of our cannabinoid-based interventions. Both aged males and
females showed similar reductions in total activity under “normal” 12:12 LD lighting
compared to their younger counterparts. This is consistent with previous studies in
humans and animal models showing that reduced locomotor activity is a common
phenotype of advanced age34,221. Mechanistically, the reduction in locomotor output with
age is primarily attributed to decreased dopamine metabolism - rather than decreased
levels in total dopamine 222. This is further supported by the finding that levodopa, a
dopaminergic and adrenergic neurotransmitter precursor, is capable of restoring some
age-related motor deficits in C57BL6 mice; though the effects of levodopa on VWR in
the context of circadian locomotion are currently unknown

223.

Although, under circadian-disrupting housing conditions (constant darkness),
sex- and age-specific differences were observed. Young male, young female, and (to a
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lesser extent) old male mice exhibit a truncated running duration (active period, α) when
housed in constant darkness (Fig. 3.3I). In comparison, the remarkably consistent
timing of activity onset and offset in young female mice suggests that this group is
uniquely resilient to the phase-disrupting effects of constant darkness (Figs. 3.2-3). One
possible explanation for the consistency observed in these young female mice is their
intact estrous cycle. Female mice undergo estropause by 12 months of age, and the
loss of these temporally consistant circulating hormones may serve to further disrupt
central pacemakers in aged females. The extent of activity onset/offset shifting seen in
the aged females (Table 3.1), coupled with significantly increased total activity in this
group indicates that aging in female mice is associated with a loss of temporal
pacemaker regulation, rather than a loss of overall pacemaker amplitude - as has been
suggested in general models of circadian-aging42,74,224,225.
Regarding the synthetic cannabinoid CP55940, short-term behavioral assays
have demonstrated that this drug is capable of eliciting both stimulatory and inhibitory
effects in a dose- and age-dependent manner. Similarly, both the phytocannabinoid
THC and the synthetic cannabinoid WIN55212-2 acutely increase DA levels in the
locomotion-regulating nucleus accumbens 226. It is currently unclear whether
cannabinoid-induced acute stimulation of dopaminergic neurons is sufficient to
chronically alter circadian rhythms, since the actions of synthetic cannabinoids on
neurons of the SCN are sensitive to GABA-A blockade 112. In addition to modulating the
excitatory/inhibitory balance of neuronal activity in the SCN, cannabinoids may directly
alter the rates of clock gene transcription via epigenetic modification. Though this
putative effect has not been directly tested in neurons of the SCN, the chronobiotic
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effects of cannabinoids might involve the long-term regulation of histone deacetylases
(HDAC) such as HDAC3 45.
Here, we confirmed that not only are the effects of CP55940 bidirectional, our
data also support the notion that high doses produce biphasic actions, such that when a
high dose is given early during the subjective daytime there is a modest increase in
activity during the subjective evening (Fig. 3.7C). It is not clear whether the evening
rebound in locomotion is due to a prolonged increase in locomotor drive, or rather just
the result of a delayed activity onset due to moderate-high doses of CP55940. To this
end, it is vital that the duration of exposure be taken into consideration, and that
extreme care is taken when extrapolating the behavioral effects of this compound
beyond the initial day of treatment in subjects of different ages/sexes (Fig. 3.8E-F). The
importance of tempering these extrapolations is perhaps most exemplified by the
exacerbated effects seen in older, but not younger mice, at the dose of 0.1mg/kg, IP.
Ultimately, the aforementioned effects of this cannabinoid on activity offset/onset
following exposure offer additional testable hypotheses that can be explored in the
context of the currently unexplained paradoxical effects induced by chronic low-dose
cannabinoid treatment in aged animals176,182.
The establishment of repeatable and rigorously defined thresholds for circadian
locomotor rhythm quantification, as evidenced in the baseline LD:DD experiments, is a
prerequisite to evaluating any potential chronotherapeutic. The use of a threshold based
off of animals’ maximum daily performance has been previously reported42. However,
thresholding activity without considering the respective age and sex of the observed
subject can hinder interpretation. Based on this, we set our threshold of 20% of animals’
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daily maximum across all days in the running wheels. Daily variations in amounts of
activity were observed across all animals throughout the experimental observation
period. Therefore, it is possible that an individual mouse’s activity was simply altered on
the three-day analysis period independent of the treatment. We tried to control for this
limitation by presenting the data both as the observed values and normalized to the day
prior to drug administration. Although computationally intense, this method as well as
thresholding based on each animal’s daily performance may provide more repeatable,
stringent quantification. Another potential limitation of this study is that a Latin Square
design was used for the repeated CP55940 injections. While this approach allows all
animals to receive all doses, it introduces a potential confound of molecular adaptations
in response to previous cannabinoid exposure - as repeated exposure to high doses of
cannabinoids can lead to changes in endocannabinoid machinery. To try and limit this,
only ‘low’ doses of CP55940 were administered; the high dose of 0.1mg/kg falls well
below the typical dosing of 0.5mg/kg CP55940 commonly used in the tetrad assay.
Additionally, treatments were given three days apart to allow for drug wash-out.
Given that in the present study our measures of activity onset and offset resulting
from either constant darkness or cannabinoid exposure were highly influenced by both
age and sex. Future studies of chronotherapeutics must take these factors into
consideration. Additionally, future studies of chronobiotics or other chronotherapeutics
should consider employing analyses of both between-group differences as well as
interindividual variability. Such analyses would not only clarify the immediate studies
being presented, but also assist in the development of relevant preclinical models for
personalized therapeutics. Taken together, these data indicate that aged mice are more
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sensitive to the synthetic cannabinoid CP55940 than young mice, and additional studies
clarifying these age- and sex-dependent mechanisms are warranted. Furthermore,
these findings present an experimental framework for testing and evaluating the
potential of chronobiotic, rhythm-restoring therapeutics.
METHODS:
Animals
All procedures were approved by the University of Mississippi Institutional Animal
Care and Use Committee (IACUC). Experimental cohorts consisted of two age groups:
2-4 months (young) and 19-24 months (old). Experiments were performed on male and
female C57BL/6NHsd mice acquired from Envigo (Cat.#: 044) or C57BL/6 mice from
the National Institutes of Aging Aged Rodent Colony. All animals were housed in the
AALAC-accredited University of Mississippi Animal Facility and given access to food
(Cat.#: 7001, Envigo Teklad 4% Fat Rodent Diet) and tap-water ad libitum for the
duration of experiments. Cohorts of mice were maintained in climate-controlled rooms
(30-40% relative humidity, 21-23°C) using a 12:12 ‘reverse’ light cycle (lights OFF at
8:00am [ZT hour 12, ZT minute 720] and ON at 8pm [ZT hour 0, ZT Minute 0). Upon
arrival into the facility, animals were immediately group-housed (4 mice/cage) in 75 in2
clear polycarbonate cages (Cat.#: AN76, Ancare) with 1/8” corn cob bedding and
environmental enrichment (Cotton Nestlets, Ancare, and Crink’l Nest, The Andersons
Lab Bedding) then allowed to acclimate to the facility for 7 days before experimentation.
Following this week of acclimation, animals were weighed, fitted with a metal ear-tag
(Cat.#: INS1005-1LSZ, Kent Scientific) and randomized into balanced experimental
treatment groups based on body weight.
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Recording Spontaneous Wheel Running
During experimentation, mice were singly-housed in 33x15x13 cm clear
polycarbonate cages (Cat.# 1144B001, Tecniplast) fitted with electronically monitored
running wheels (PT2-MCR1, Actimetrics). Photoelectric sensors attached to each cage
recorded wheel rotations and transmited the data to a nearby desktop computer which
was remotely monitored to limit unnecessary entries into the room. For the duration of
each experiment (28 days, maximum) each wheel’s rotations per minute were recorded
using the ClockLab software (Actimetrics). Prior to beginning the experiment, each
wheel was lubricated using a food-grade silicone spray (03040, CRC) and calibrated to
ensure even resistance between wheels. Mice were checked daily, and clean cages
were replaced every week. All experimental handling and procedures were performed
under very dim red light (<1lux) during the animals’ active period (lights OFF, ZT hour
12 through ZT hour 24/0).
Experimental Timeline
During baseline quantification of age- and sex- specific behaviors, mice were
placed into the prepared running wheel cages and allowed to freely run for 7 days.
Shortly before lights-on at the end of day 7, a custom-fabricated breathable light-proof
fabric was used to cover the entire cage rack and eliminate light-associated cues. Mice
were remotely monitored for seven additional days under constant darkness before
being removed and returned with their original cage mates. Separate cohorts of animals
were used to assess the chronobiotic potential of CP55940 and were tested only under
normal lighting conditions (12:12, LD). For the CP55940 experiments, animals were
allowed to freely run on the wheels for 14 days prior to drug administration. At the start
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of the 15th day of running, immediately after the onset of animals’ subjective active
period (30-60 minutes after lights OFF, 8:30-9:00am, ZT hour 12.5-13) animals were
briefly removed from their cages and administered one of four doses of vehicle or
CP55940 via intraperitoneal injection before being immediately returned to their running
wheel cages. Following the initial dose, animals were administered a new unique dose
of vehicle or CP55940 every 72 hours until each animal had received all 4 doses.
Drugs, Dosing, and Administration
The synthetic cannabinoid CP55940 (Cat.#:0949, Tocris) was initially diluted in
100% ethanol (Cat.#:2701, Decon Labs) to a stock concentration of 10mg/mL and kept
at -20°C. On the day of each experiment, fresh vehicle solution was prepared by first
dissolving Kolliphor EL (formerly known as Cremophor EL, Cat.#: C5135-500G, Sigma
Life Science) in 100% ethanol, then adding sterile 0.9% HSP pH 7.4 saline (Cat.#:
00409488810, Hospira) in a ratio of (1:1:18, ethanol:Kolliphor:saline). All drug
concentrations were administered at a volume of 1mL/100g body weight. On the day of
testing, immediately after the onset of animals’ subjective active period (30-60 minutes
after lights OFF, 8:30-9:00am, ZT hour 12.5-13) the animals’ weights were recorded,
then a body weight-adjusted dose of vehicle or CP55940 was administered via
intraperitoneal (IP) injection. All injections were performed under very dim red light using
a 1mL syringe (Cat.# 309602, Becton, Dickinson and Company[BD]) and a 25 gauge
needle (0.5 x 16mm, Cat.# 305122, BD).
Body Weight
Body weight was measured at the start of every experimental procedure to
ensure accurate drug administration and as an endpoint for exclusion in the event that
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an animal’s mass decreased >10% in a week. Animals were gently removed from their
cages by lightly gripping the base of their tail and placed into a lidless pipette-tip box on
top of the balance. Once the animal ceased moving the mass was recorded. In between
recordings, the pipette-tip box was wiped clean with 70% ethanol, dried with a paper
towel, and the balance was tared.
Data Acquisition, Quantification of Rhythms, and Statistical Analysis
Data were collected, processed, analyzed, and visualized using a combination of
ClockLab (v3.60, Actimetrics), Microsoft Excel (v2016, Microsoft), RStudio (v.1.1.456,
RStudio Team) and numerous R-packages227-239, MATLAB (r2019a, MathWorks), and
Inkscape (v0.92.3). After the completion of all experiments, raw wheel counts were
exported from ClockLab to comma-delimited files and imported to MATLAB for
annotation and inspection. All wheel counts were annotated with the animal’s age, sex,
date and time of acquisition, and experimental treatment. In cases where spurious data
points were identified due to sensor failures, pre-processing of the data was performed
prior to analysis. In such cases, pre-processing involved identifying the timepoints of
clearly spurious values (e.g. sustained wheel RPMs of >300 for several hours) were
noted, and data values were replaced with 3-minute averages from exactly 24 hours
before and after the noisy sections. All experiments began with n=12 running wheels,
and recordings which contained spurious values in excess of 10% of the total recording
were excluded from further analysis. During baseline (LD/DD) testing, one young male
and one old males’ recordings were excluded due to sensor failures. During CP55940
testing, three young male, 6 young female, 4 old male, and 4 old female recordings
were excluded due to sensor failures.
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After pre-processing of the data, surface plots of daily locomotion were produced
in MATLAB for visualization of transitions from normal lighting to constant darkness
(Fig. 3.2-3.8) as well as responses to CP55940 treatment (Fig. 3.4-3.8). Quantification
of rhythm properties was accomplished using a combination of MATLAB and R,
consisting of the following steps. First, a 10-minute moving-average was applied to each
animal’s raw wheel counts. Next, each animals’ average daily rotations per minute
(RPMs) were calculated. The minute-by-minute daily averages were then used to
compute the Activity Onset and Activity Offset, which were defined as the first 10-minute
period of time whose average values were greater or less than 20% of that animal’s
average daily maximum. Calculation of running period was accomplished by first
generating Lomb-Scargle periodograms of each animal’s wheel counts within a given
lighting condition, then selecting the most prominent peak present in the periodogram.
The corresponding value of each peak was used for comparative period lengthening
and shortening in constant darkness.
Finally, statistical comparisons between treatment groups were performed. The
independent variables for baseline recordings were: age, sex, and light schedule. In the
second set of experiments using CP55940, the independent variables were: age, sex,
and dose of CP55940 with day of injection as a blocking variable. Prior to omnibus
testing, all data for a given measurement was tested for outliers, which was defined as
those points that were greater or less than three interquartile ranges above or below the
3rd and first interquartile ranges within a single treatment group. After exclusion of these
points, data from each measurement were assessed for a normal distribution (ShapiroWilk test) and equal variance (Levene test). A 3-way ANOVA was used to assess
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differences between treatment groups. A priori significance was set at =0.05.
Significant main-effects and interactions detected in omnibus tests were followed by
additional planned contrasts. In the preliminary experiments, the ANOVA model used
was Age:Sex:Lighting_Conditions. In the experiments using CP55940, the ANOVA
model used was Age:Sex:Dose_CP55940. Additionally, 1-way ANOVA testing was
performed on total wheel rotations measured in experiment two to assess dosedependent changes within a single age/sex group. To determine the proportion of
animals which were classified as early-, consistent-, or later risers, Fisher’s Exact Test
followed by pairwise nominal independence post hoc tests were used. The false
discovery rate was corrected for using the Benjamini, Hochberg, and Yekutieli method.
Data and Code Availability
All original data and code used for analysis are available upon reasonable
request to the corresponding author, Nicole M. Ashpole (nmashpol@olemiss.edu).
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FIGURES

B

A

Figure 3.1: Experimental timeline of baseline wheel running and treatment with
CP55940.
Panel A) Cohorts of young and old male and female mice were singly housed in cages
with remotely monitored running wheels for a total of 14 days. During the first 7 days,
mice were exposed to normal lighting (12 hours of light and 12 hours of darkness). After
7 full days, mice were held in constant darkness for an additional 7 days while wheel
running was recorded.
Panel B) Separate cohorts of young and old male and female mice were allowed two
weeks of acclimation running under normal 12:12 lighting. Beginning on day 14, one
hour after lights off at the beginning of the animal’s active period, mice were
administered the first of four unique doses (0 [vehicle], 0.001mg/kg, 0.01mg/kg,
0.1mg/kg) of the synthetic cannabinoid CP55940 via intraperitoneal injection. Mice were
then left undisturbed for two days. Every 3 days (indicated in green), animals were
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administered an additional unique dose, according to a Latin-square experimental
design.
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Figure 3.2: Circadian locomotion of C57BL6 mice housed under normal lighting (12:12,
LD) and constant darkness (00:24, DD).
Panels A-D) Surface plots of minute-by-minute activity during 7 days of normal (12:12)
lighting and 7 days of constant darkness (indicated by the black or white squares under
each surface).
Panels E-H) Hour-by-hour average daily means, maxima, and periods of C57BL6 Mice
housed under normal lighting and constant darkness. Lights off was defined as
Zeitgeber Time (ZT hour 12).
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Figure 3.3: Quantification of changes in average activity onset, activity offset, duration of
activity, and total activity during normal lighting and constant darkness.
Panels A-B) Average time of activity onset during normal lighting (A) and constant
darkness (B).
Panel C) The relative change in timing of activity onset between normal lighting and
constant darkness.
Panels D-E) Average time of activity offset during normal lighting (D) and constant
darkness (E),
Panel F) The relative change in timing of activity offset between normal lighting and
constant darkness.
Panels G-H) Average total minutes of activity during normal lighting (G) and constant
darkness (H),
Panel I) The relative change in average duration of activity between normal lighting and
constant darkness.
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Panels J-K) Average total wheel rotations during normal lighting (J) and constant
darkness (K),
Panel L) The relative change in average total wheel rotations during normal lighting and
constant darkness. Significant differences (p<0.05) between sexes within an age group
are indicated by (*), while significant differences between ages within a sex are
indicated by (#).
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Age
Sex n=
Young Male 11
Old
Male 11
Young Female 12
Old Female 12

Early

Activity Onset
(% ) Consistent (% )

Late

(% )

Early

Activity Offset
(% ) Consistent (% )

Late

(% )

8

(72.7)

2

(18.2)

1

(9.1)

8

(72.7)

2

(18.2)

1

(9.1)

6

(54.5)

2

(18.2)

3

(27.3)

6

(54.5)

2

(18.2)

3

(27.3)

3

(27.3)

3

(27.3)

6

(54.5)

3

(27.3)

3

(27.3)

6

(54.5)

11

(100.0)

1

(9.1)

0

(0.0)

11

(100.0)

1

(9.1)

0

(0.0)

Table 3.1: Proportion of animals whose activity onset and offset shifted greater than 15
minutes from normal lighting to constant darkness.
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Figure 3.4: Treatment with varying doses of the synthetic cannabinoid CP55940 in
young and old male mice.
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Average running wheel activity of young (2-4m) and old (18-22m) male mice was
quantified the day before (back, day 1), during (middle, day 2), and after injection (front,
day 3). Data plotted as Day of Running 2 represent the average group activity following
one of four doses of CP55940 (0 [Vehicle], 0.001, 0.01, or 0.1mg/kg, IP). Lights-on was
defined as ZT minute 0, and lights-off was defined as ZT minute 720. Each mouse
received all 4 doses in a pseudo randomized order. All mice had a 72-hour washout
period between subsequent injections.
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Figure 3.5: Treatment with varying doses of the synthetic cannabinoid CP55940 in
young and old female mice.
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Average running wheel activity of young (2-4m) and old (18-22m) male mice was
quantified the day before (back, day 1), during (middle, day 2), and after injection (front,
day 3). Data plotted as Day of Running 2 represent the average group activity following
one of four doses of CP55940 (0 [Vehicle], 0.001, 0.01, or 0.1mg/kg, IP). Lights-on was
defined as ZT minute 0, and lights-off was defined as ZT minute 720. Each mouse
received all 4 doses in a pseudo randomized order. All mice had a 72-hour washout
period between subsequent injections.
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Figure 3.6: Voluntary wheel running of young and old male and female C57BL6 mice on
the day before, during, and after injection with varying doses of CP55940.
On the day of injection, 30-60m after lights off (~ZT hour 12.5) mice were administered
an intraperitoneal injection of vehicle or varying doses of CP55940 and returned to their
running wheels. Doses of CP55940 are (Zero [Vehicle], Low [0.001mg/kg], Med
[0.01mg/kg], High [0.1mg/kg]). Lines and error bars represent the average group mean
(n=6-9 per dose). Dashed lines indicate maximum rotations per minute (RPM) for a
given dose. Dotted lines indicate mean RPM for a given dose.
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Figure 3.7: Quantification of total wheel running 1, 1-6, and 6-12 hours after injection of
the synthetic cannabinoid CP55940.
On the day of injection, 30-60m after lights off (~ZT hour 12.5) mice were administered
an intraperitoneal injection of vehicle or varying doses of CP55940 and returned to their
running wheels. Doses of CP55940 are (Zero [Vehicle], Low [0.001mg/kg], Med
[0.01mg/kg], High [0.1mg/kg]). Total wheel running was quantified by summing the
rotations per minute for the given durations listed.
Panel A) Total wheel rotations in the first hour after injection.
Panel B) Total wheel rotations for the first 6 hours after injection.
Panel C) Total wheel rotations 6-12 hours after injection.
Significant differences (p<0.05) between sexes are indicated by (*), while significant
differences between ages are indicated by (#). Significant differences between a dose
of CP55940 and the vehicle within a sex/age group are indicated by (@).
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Figure 3.8: Quantification of changes in average activity onset, activity offset, duration of
activity following injection of the synthetic cannabinoid CP55940.
On the day of injection, 30-60m after lights off (~ZT hour 12.5) mice were administered
an intraperitoneal injection of vehicle or varying doses of CP55940 and returned to their
running wheels. Doses of CP55940 are (Zero [Vehicle], Low [0.001mg/kg], Med
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[0.01mg/kg], High [0.1mg/kg]). Activity onset and offset were calculated based on the
time at which an animal reached 20% of its maximum daily RPM.
Panel A) Average time of activity offset on the day of injection.
Panel B) Change in the time of activity offset from the day before injection.
Panel C) Total minutes spent running at a rate above 20% of each animal’s daily
maximum RPM on the day of injection.
Panel D) Change in running duration (day of injection - day before injection).
Panel E) Average time of activity onset on the day after injection.
Panel F) Change in the time of activity onset (day after injection - day before injection).
Significant differences (p<0.05) between sexes are indicated by (*), while significant
differences between ages are indicated by (#). Significant differences between a dose
of CP55940 and the vehicle within a sex/age group are indicated by (@).

90

CHAPTER 4:
CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS
GRAPHICAL ABSTRACT:

SUMMARY OF FINDINGS:
Aging Circadian Rhythms and Cannabinoids
While exploring the possibility that circadian rhythms and aging are inextricably
linked, it became clear that this idea is not novel. In fact, preliminary literature searches
indicated that more publications exist regarding the relationship of aging to circadian
rhythms than any other components of this work (Figure 4.1). Despite this shared,
persistent interest, there are still numerous outstanding questions pertaining to the
relationship between circadian rhythms and biological aging. The most glaringly obvious
of which is: does the circadian molecular machinery regulate lifespan directly, or is it the
collective functional output of these internal clocks? Chapter 1 summarized the findings
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from over 150 articles on biological aging, circadian rhythms, and cannabinoid
pharmacology and highlighted several theoretical and experimental breakthroughs
which have led the field thus far. In particular, the works of Colin Pittendrigh, Jürgen
Aschoff, and Arthur Winfree profoundly shaped Chapter 1 and the hypotheses it
contains. Collectively, their pioneering work revealed the experimental tractability,
pervasiveness, and scale-invariance of biological clocks. The fundamental postulate of
Chapter 1 is that circadian rhythms are not only an observable physiological
phenomenon throughout the lifespan, but that their manifestation directly influences the
rate of biological aging. If we accept the present evidence - that deteriorating circadian
rhythms precede the onset of many age-related pathologies - then it stands to reason
that the maintenance of the output generated by these molecular clocks may very well
stave off pathologies of aging (Figure 1.5).
Substantial evidence correlates the molecular and cellular mechanisms of
dysregulated circadian rhythms with constituents of the endocannabinoid system.
Although much is known about the endocannabinoid system and its regulation of
neuronal activity and rodent behavior, there are significant gaps in knowledge regarding
endocannabinoid function in advanced age. Limited knowledge about the effects of
these compounds in aged subjects coupled with rapidly expanding access to
exogenous cannabinoids marketed as therapeutics has placed elderly members of our
society at risk for potentially adverse effects. Specifically, these previous gaps in
knowledge precluded inferences of cannabinoid-elicited responses in aged animals which were directly tested in Chapter 2.
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Overwhelming evidence of cognitive impairment following high-doses of
exogenous cannabinoids has led many to believe that these pharmacological agents
lack therapeutic value. Nevertheless, the studies cited in Chapter 1 support the
hypothesis that extremely regimented application of CB1 agonists at low doses may
benefit certain age-related physiological dysfunctions. Capitalizing on the bidirectional
dose-response (hormesis) which was been previously reported in young animals given
exogenous cannabinoids, we hypothesized that cannabinoids are capable of both
stimulating and suppressing circadian output in a time-dependent manner (Figure 1.5).
To date, most studies have focused on melatonin for its ability to exhibit this circadian
rhythm-modulating chronobiotic effects, though it is highly probable that many other
pharmacological agents function in this manner59,60. Since cannabinoid receptors are
present in the SCN, and exogenous cannabinoids modulate neuronal activity
responsible for thermoregulation and locomotion, the conclusions drawn from this
chapter warranted further investigation of these substances in aged subjects and
models circadian rhythm disruption.
Cannabinoid Hormesis
The previously hypothesized potential benefits from cannabinoid-based
chronotherapeutics are directly proportional to the bidirectional (hormetic) doseresponses they produce. To this end, application of certain cannabinoids at calculated
doses would theoretically allow for the rescue of both overactive and underactive
biological processes. Such flexibility in a therapeutic agent, at least in theory, would
surely be advantageous. Therefore, the work described in Chapter 2 was directly aimed
at answering the following questions:

93

1) Do young and old animals differ in their physiological or behavioral responses
to exogenous cannabinoids?
2) Are exogenous cannabinoids capable of eliciting both stimulation and
inhibition of body temperature, locomotion, or nociception in mice?
3) Are the stimulatory effects of exogenous cannabinoids restricted to a single
time-point in the lifespan?
After testing over 250 young and old mice from 3 independent cohorts and performing
15 iterations of the Tetrad Assay, we concluded that the synthetic cannabinoid
CP55940 is both more potent and efficacious in its ability to induce hypolocomotion,
hypothermia, and antinociception in aged mice. Additionally, our data indicated that the
hormesis-like stimulation induced by low doses of this exogenous cannabinoid were
evident and most pronounced in locomotor readouts from young, male mice.
Cannabinoids as Chronobiotics
The stimulation of locomotion by low-doses of CP55940 observed in experiments
from Chapter 2 was quite compelling, and supported the hypothesis put forth in Chapter
1. Synthesizing our work and others’, it has now been demonstrated that cannabinoids
are able to alter neuronal activity, locomotion, and thermoregulation in a bidirectional
manner. Therefore, the ability of these compounds to flexibly alter both central and
peripheral clock function seems plausible. To experimentally test this we first needed to
quantify baseline measures of circadian wheel running, then compare the ability of
CP55940 to modulate these measures. The experiments described in Chapter 3
highlight the importance and technical difficulty of experimentally measuring circadian
rhythms.
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Under baseline normal lighting conditions, female mice produced more wheel
rotations than age-matched male mice, although the duration of activity was not
different between the sexes (Fig. 3.3). These findings agree with previous work
reporting that female C57BL6 mice are more active than males240,241. However, we were
surprised by the shortening of animals’ active periods following transition to constant
darkness (Fig. 3.2). Despite increased total number of wheel rotations in constant
darkness (Fig. 3.3L), young male and female mice actually shortened their durations of
activity (Fig. 3.3I). Furthermore, the resilience of young female mice to circadian
disruption in constant darkness, as well as the loss of this resilience with age are
significant findings from this study.
To evaluate the potential of CP55940 to alter circadian locomotor rhythms, we
chose to administer low to moderate doses of this drug at the beginning of animals’
active periods. Although we did not detect significant stimulation of total wheel running
in response to low doses of CP55940 (Fig. 3.7B), we were intrigued by the temporally
biphasic suppression and stimulation of locomotion seen at higher doses. This evening
‘rebound’ in locomotion may partly explain why previous studies have inconsistently
reported locomotor depression and stimulation with modestly low doses of exogenous
cannabinoids242. Collectively, the presence of Age:Sex interactions in many of the
metrics we reported further solidifies the need to include and transparently report these
factors in future studies.
LIMITATIONS AND FUTURE DIRECTIONS:
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Existing Data and Tools
It may seem obvious that some aspects of these experiments have been tested
previously, however, the lack of freely available well-annotated data have prevented
scientists’ ability to conduct these vital comparisons post hoc. As modern technology
and data repositories seek to remedy these issues, a major benefit of the work
described here is the production of a curated, highly annotated, shareable data set. The
wealth and density of information present in these data are immeasurable, and it would
be foolish to consider the current analysis as ‘complete’. Accordingly, future studies
utilizing the data produced during vehicle-acclimation described in Chapter 2 or the
baseline wheel recordings discussed in Chapter 3 may yield additional insights.
The evaluation of CP55940 as a chronobiotic was technically challenging for
numerous reasons, partly because there are no commercial tools currently available to
rigorously and efficiently conduct this analysis. Therefore, the success of this entire
project directly relied on the ability to generate effective and efficient methods for data
collection, curation, and analysis. The primary code and programs written to perform
these tasks have been compiled in the Appendix. Additionally, the present success of
these analytical tools now permits high-throughput testing of the chronobiotic effects of
not only cannabinoids but also drugs of abuse and other potential therapeutics.
Mice as a Model for Circadian Rhythm Disruption
The translation of experimental findings from rodents to humans is contentious,
to say the least243. However the value of preclinical rodent models in biological aging
research is undeniable244,245. Despite the immense knowledge gained from research on
rodent circadian rhythms, the usefulness of these nocturnal animals as a model for
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potential chronotherapies in humans remains to be evaluated. From a chronobiology
standpoint, rodents (like most other mammals studied thus far) possess homologous
core clock molecules22. Nevertheless, mice are nocturnal and exhibit distinct melatonin
rhythms compared to diurnal humans. The release of melatonin from the human pineal
gland exhibits a robust circadian rhythm whose peak onset corresponds to evening
reductions in light. In contrast, mice exhibit a mid-subjective-day spike in melatonin
secretion that occurs ~8 hours after the onset of darkness246. This surge in melatonin
may be partly responsible for the mid-day ‘siesta’ observed in the baseline recordings
presented in Chapter 3 (Fig. 3.2). Considering that melatonin is the most well-studied
chronobiotic in humans, future studies should compare the temporal release of
melatonin in mice treated with novel chronobiotics247.
Mitigation of Circadian Confounds
Another major benefit of the present work over previous studies is that all
experimental procedures were performed in the dark, during the animals’ active cycle.
The time of day at which a drug is administered profoundly affects its metabolism and
efficacy, and the study of these collective time-of-day-effects is known as
chronopharmacology. Early work with cannabinoids clearly demonstrated that the
effects of these compounds are significantly lowered when administered during the
animals’ inactive period189. Therefore, testing animals in the dark while they are active,
although technically challenging, is a vital factor to consider when translating these
findings to humans.
In addition to these chronopharmacological effects, behavioral endpoints such as
locomotion are clearly variable throughout the day (Fig. 3.2). Indeed, meta-analysis of
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the thermoregulatory responses to vehicle injection were shown to vary depending on
the time of injection (Fig. 4.2). In the tetrad-based experiments described in Chapter 2,
the number of animals which needed to be tested in a single day coupled with a limited
number of testing apparatuses necessitated testing animals at varying times during their
active period. Although all doses were represented at all time points, we were unable to
completely alleviate the potential confound of circadian effects on these physiological
and behavioral readouts. Given that the exact time and order of all experiments was
included in the annotated data set, it may be possible with future analysis to determine
the extent that time-of-administration, and even time of year (Fig. 4.3), may have
influenced the present findings.
Vehicle, Drug, and Route of Administration
Throughout these studies, great care was taken to mitigate the effects of the
injection procedure and vehicle administration. Although the relative concentrations of
ethanol and detergent (Kolliphor EL) in the vehicle far exceed the concentration of
cannabinoid, the profound effects of CP55940 are observable even at the lowest dose
tested (0.001mg/kg, IP). The 1:1:18 (ethanol:Kolliphor:saline) ratio used as a vehicle
here was based off of numerous previous reports using this vehicle in studies of THC
and CP55940139,248,249. Still, we observed modest but consistent changes in body
temperature responses to vehicle injection (Fig. 4.3). Evaluation of vehicle specific
effects per se was not the intent of these studies, however, future well controlled studies
evaluating the continued use of this mixture as a vehicle should be performed.
The intraperitoneal injection of CP55940 is a potential limitation of these studies,
as this route of administration does not translate well to human cannabinoid usage.
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While the availability of purified phytocannabinoids increases in the United States, many
additional studies of the age-, sex-, and dose-dependent effects of isolated
phytocannabinoids and cannabis-derived terpenes are now warranted126,127,158,160.
Accurately modeling human routes of administration in rodents has traditionally been
difficult, though recent advances in electronic vaporization devices may revolutionize
models of inhalation160. In addition to models of cannabinoid inhalation, oral ingestion of
cannabinoid-containing products is increasing specifically among elderly patients and
should be further investigated.
Experimental Design of Hormesis Study
In order to facilitate the rapid acquisition of multiple behavioral endpoints while
mitigating the effects of repeated dosing, it was necessary to perform the behavioral
tests in Chapter 2 as a 1.5 hour-long battery. In this experimental design, we first took
baseline rectal and IR temperature recordings, weighed the animals, then injected the
drug. Thirty minutes later, animals were placed in the open field and allowed to explore
for 30 minutes. At the conclusion of open field testing, animals’ temperatures were then
taken again prior to nociception testing using the hot-plate and tail-withdrawal assays. A
major limitation of this approach was discovered when comparing the thermoregulatory
responses of vehicle-treatment during acclimation to vehicle-treated animals during the
behavioral battery. The most likely explanation for these discrepancies is the stress and
increased locomotion resulting from animals being tested in the open field between
temperature recordings. Considering that low-dose hyperthermia was intended to be a
primary readout of this study, the hyperthermia (likely) induced by open field testing
potentially occluded true differences.
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The previously mentioned hyperthermia observed following open field testing
highlights the importance of choosing, whenever possible, assays with large dynamic
range. Since the average body temperature of mice in our study was ~37.5°C, and the
maximum rectal temperature recorded was 39°C, it is also conceivable that a ‘ceiling
effect’ occluded potential hyperthermia induced by low-doses of CP55940. Similarly,
during hot-water tail withdrawal experiments, vehicle-treated animals withdrew their tails
from 48°C water in less than 2 seconds. Such rapid responses by these vehicle-treated
mice left little room to detect potentially hyperalgesic effects elicited by low doses of
CP55940.
Voluntary Wheel Running
The use of voluntary wheel running to assess circadian locomotion is widespread
in rodent research. Yet recent evidence indicates that access to a running wheel and
the requisite social isolation both profoundly alter physiology and behavior241,250-252.
Furthermore, limitations imposed by the design of currently available commerciallyproduced running wheels hinders their use in longitudinal studies of aging. Future
studies utilizing telemetric systems may greatly improve the quality of this research, as
modern technology now permits simultaneous long-term recording from group-housed
mice. Additionally, the use of telemetry for chronobiotic studies also presents the
additional advantage of simultaneously monitoring body temperature with far greater
temporal resolution than is capable with a rectal probe.
BIOLOGICAL AGING AND CIRCADIAN RHYTHMS AS DYNAMICAL SYSTEMS
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Though the process biological aging has previously been referred to as a
stochastic (random), several lines of research suggest that aging systems are not
random - but rather chaotic253,254. In support of this, adaptation of the “two-hit
hypothesis” from cancer research to the biology of aging has left open the possibility
that the aging systems may actually exhibit features of dynamical systems - that is to
say that they are calculable, if the starting conditions are known255-257 258. The biological
importance of these high-dimension mathematical properties remains unknown, though
the presence or absence of these fractal patterns may correspond to the onset of agerelated neuropathology37. Future studies employing these advanced computational
analyses are likely to yield valuable insight regarding the onset, progression, and
treatment efficacy of age-related diseases.
CONCLUSION
The work contained in this dissertation proposes and tests the novel hypothesis
that cannabinoid hormesis can be used to bidirectionally modulate age-related changes
in circadian locomotion. Throughout these studies, pronounced age-, sex-, dose-, and
time-dependent effects were observed in the physiological and behavioral responses to
treatment with exogenous cannabinoids. Testing of this hypothesis required the creation
and validation of novel behavioral paradigms, analytical tools, unique technical
approaches, and established a framework for evaluating chronobiotic compounds in
aging mice. Furthermore, the data collected in these studies has been compiled in a
manner that facilitates future analysis and continued usefulness. Collectively, these
findings indicate that the exogenous cannabinoid CP55940 possesses hormetic and
chronobiotic characteristics in young mice, but the increased sensitivity to this
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compound in aged mice suggests that therapeutic applications of cannabinoids in
elderly patients must be approached with caution.
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FIGURES

Figure 4.1: Frequency of word-cluster combinations present in a systematic literature
search.
Complex clusters of related strings were created to systematically search online
databases for relevant literature when writing Chapter 1. The relative number of hits for
each combination of word clusters is listed below and coded in a heat map. Search
conducted via One Search in November 2018.
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Figure 4.2: Time-of-day effect on thermoregulatory response to vehicle injection during
acclimation trials.
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Figure 4.3: Time-of-year effect on housing room humidity.
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MATLAB CODE
Step 1 - Import Merged CSV Counts
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
%%%%%

Running_Wheel_Analysis_MASTER (February 2020) - Erik Hodges

%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
% This program takes in exported ClockLab Counts (.csv) which have been
% consolidated using Excel macros stored in the
% "Format_Counts_Master_May.xlsm" file. The goal of this script is to
% reformat the DateTime for Zeitgeber Time (ZT) and save the formatted
file
% as a .mat for future analysis.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
% Clear All Current Variables and Console
%
clear all;
close all;
clc
%}
format long;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%

Importing
Data%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%
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File_Folder = 'C:\Users\erikh\Desktop\Lab Notebook\DATA\Running
Wheels\Data_Analysis\Data\Input\Merged_Raw_In_Excel\**\*.csv';
CSV_Directory = dir(File_Folder);

for i = 1:numel(CSV_Directory)
CSV_Files(i) = string(CSV_Directory(i).name);
end

CSV_Files = CSV_Files(1:end)';

for q = 1:numel(CSV_Files)

% This was added in to specifically remake the
% CP_YF_3.mat file after realizing that the original recordings
hadn't
% adjusted for DST and therefore were out of sync with the lights,
since
% the animals were becoming active at 9:00 and 21:00. If working with
% this data set in the future, please confirm that CP_YF_3 is
adjusted
% by -1 hours and that ZT is calculated correctly. This is done by
% looking through this code and adding back the "if" statements that
% target file == "CP_YF_3.csv"
%

if file == "CP_YF_3.csv";

% file = 'CP_YF_3.csv';
file = CSV_Files(q);
opts = detectImportOptions(file);
opts = detectImportOptions(file,'DatetimeType','text');
ImportedData = readtable(file,opts);
% For some reason when the data is imported there is a large chunk of
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empty cells added to the end of the recording
ImportedData(ImportedData.Date=="",:) = [];

This formats the DateTime as it comes out from ClockLab

ImportedData.NewDateTime = strcat(ImportedData.Date,{'
'},ImportedData.Time);
ImportedData = movevars(ImportedData, 'NewDateTime', 'Before',
'Day');
ImportedData.NewDateTime =
datetime(ImportedData.NewDateTime,'InputFormat','dd-MMM-yy HH:mm');

NewDateTime = ImportedData.NewDateTime;
NewDateTime.Format = 'MMM-dd-yyyy HH:mm:ss';
ImportedData.Date = NewDateTime;
ImportedData.Properties.VariableNames(1) = {'DateTime'};
ImportedData_Columns = ImportedData.Properties.VariableNames'; %save
the header text as a variable
ImportedData.Time = [];
ImportedData.NewDateTime = [];
ImportedData.Day = [];
ImportedData.Hr = [];
if any(ImportedData_Columns() == "Min") > 0
ImportedData.Min = [];
end
clear('NewDateTime','opts');
ImportedData_Columns = ImportedData.Properties.VariableNames'; %save
the header text as a variable
ExpNames = {'Base_YM_1';'Base_OM_1';'Base_YF_1';'Base_OF_1';...
'CP_YM_1';'CP_YM_2';'CP_YM_3';'CP_YF_1';'CP_YF_2';'CP_YF_3';'CP_OM_1';'CP
_OF_1';...
'Pilot_Cipro_1';'Pilot_OM_1'};
% This if statement is to adjust for the fact that the computer

140

didn't recognize DST during CP_YF_3
%
if file == "CP_YF_3.csv"
ImportedData.DateTime = ImportedData.DateTime - hours(1);
end
%}
%}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%

Define Experimental Variables

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
fs = 1/60; % Sample rate, which is set in ClockLab (1 minute =
1/60sec)
MinutesInDay = 1440;
LightsOffHr = 8; % Input the time that lights turn off
LightsOnHr = 20; % Input the time that lights turn on
LightsOffMinute = LightsOffHr * 60; % This corresponds to 8:00am
LightsOnMinute = LightsOnHr * 60; % This corresponds to 8:00pm
%}

ZT Data Padding to BEGINNING of Record

% AFTER RUNNING INTO THE PROBLEM WHERE I NEEDED TO PAD THE END OF THE
% RECORDINGS I DISCOVERED A BETTER WAY TO "ROUND" THE RECORDINGS AND
% EMPLOYED THIS METHOD TO ROUND THE END OF THE RECORDINGS UP TO
% 20:00:00, HOWEVER I DID NOT GO BACK AND EMPLOY THIS METHOD TO THE
% PADDING AT THE BEGINNING OF THE RECORDINGS, BUT I SHOULD DO THIS IN
% THE FUTURE.
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% New NaN padding to the front of a time series so that ZT can be
% calculated from the moment of LIGHTS ON (20:00:00)

FirstTime = min(ImportedData.DateTime);
NewStart = FirstTime-hours(4); % By doing it this way it does not
adjust for the case when I have to -1 hour for DST

% This if statement is to adjust for the fact that the computer
didn't recognize DST during CP_YF_3
%
if file == "CP_YF_3.csv"
NewStart = FirstTime-hours(3);
end
%}
TimeDiff = NewStart - FirstTime;
PadTable = ImportedData(1,:);
PadTable(2,:) = PadTable(1,:);
PadTable{2,2:end} = NaN;
Time2Add = FirstTime+TimeDiff; %-'00:01:00'; %might need to add this
extra minute back at some point
PadTable{2,1} = Time2Add;
TTpad = table2timetable(PadTable);
TTadd =
retime(TTpad,'regular','fillwithmissing','TimeStep','00:01:00');
TTadd(end,:) = [];
TTadd = timetable2table(TTadd);
PaddedData = [ImportedData;TTadd];
ImportedData = PaddedData;
ImportedData = sortrows(ImportedData,'DateTime','ascend');

ZT Data Padding to END of Record

% In this case it is not always clear that it is optimal to 'trim'
the
% final day to end on 20:00:00, therefore I will write a block of
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code
% to pad (round up) the last day to 20:00:00
LastTime = max(ImportedData.DateTime); % Jan-18-2019 15:59:00
NewEnd = LastTime;
NewEnd.Hour = 20 * ceil(NewEnd.Hour/20); % Jan-18-2019 20:59:00
NewEnd.Minute = floor(NewEnd.Minute/60); % Jan-18-2019 20:00:00

EndDiff = NewEnd - LastTime;
PadTable = ImportedData(end,:);
PadTable(2,:) = PadTable(end,:);
PadTable{2,2:end} = NaN;
Time2Add = LastTime+EndDiff; %-'00:01:00'; %might need to add this
extra minute back at some point
PadTable{2,1} = Time2Add;
TTpad = table2timetable(PadTable);
TTadd =
retime(TTpad,'regular','fillwithmissing','TimeStep','00:01:00');
%

TTadd(end,:) = []; % I believe I want to keep this last row, so the

recording ends at an even 20:00:00
TTadd = timetable2table(TTadd);
TTadd(1,:) = []; % I introduced a duplicated row and need to get rid
of it before merging with the ImportedData
PaddedData = [ImportedData;TTadd];
ImportedData = PaddedData;
ImportedData = sortrows(ImportedData,'DateTime','ascend');
% This if statement is to adjust for the fact that the computer
didn't recognize DST during CP_YF_3
% This is a terrible way of doing this, but I don't have time to fix
this more elegantly
%
%

if file == "CP_YF_3.csv"

%
%

NewEnd = LastTime-hours(3);
end
%}
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ImportedData = ImportedData(ImportedData.DateTime<=NewEnd,:);

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%

Data Organization and Orientation

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%

Create Timeline Variables for ZT, such as minutes/hours/etc.

DataLength = height(ImportedData);
ZTDur = ImportedData.DateTime;
ZTDur = ZTDur - ZTDur(1);
ImportedData.ZTDuration = ZTDur;
ImportedData.ZTDay = days(ImportedData.ZTDuration);
ImportedData.ZTHour = hours(ImportedData.ZTDuration);
ImportedData.ZTMinute = minutes(ImportedData.ZTDuration);
ImportedData.ZTDayBin = fix(ImportedData.ZTDay);
ImportedData.ZTHourBin = fix(ImportedData.ZTHour);
ImportedData.ZTMinuteBin = fix(ImportedData.ZTMinute);
for i=1:DataLength
if ImportedData.ZTDayBin(i) >= 1
ImportedData.ZTHourBin(i) = ImportedData.ZTHourBin(i)(24*ImportedData.ZTDayBin(i));
ImportedData.ZTMinuteBin(i) = ImportedData.ZTMinuteBin(i)(1440*ImportedData.ZTDayBin(i));
end
end
ImportedData.ClockHourBin = hour(ImportedData.DateTime);
ImportedData.ClockMinuteOfDay =
(ImportedData.ClockHourBin*60)+(minute(ImportedData.DateTime));
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ImportedData = movevars(ImportedData,
{'ZTDuration';'ZTDay';'ZTHour';'ZTMinute';'ZTDayBin';'ZTHourBin';'ZTMinut
eBin';'ClockHourBin';'ClockMinuteOfDay'}, 'After',1);
%clearvars -except ImportedData Base_YM_1 ExpNames Files
ImportedData_Columns = ImportedData.Properties.VariableNames'; %save
the header text as a variable
New_File_Name = strrep(file,'.csv','.mat');
assignin('base',strrep(file,'.csv',''),ImportedData)
save(New_File_Name,strrep(file,'.csv',''))

end

Step 2 - Add Metadata
% Clear All Current Variables and Console
%
clear all;
close all;
clc
%}
format long;

Load Files

Files = {...
'Base_YM_1.mat';'Base_YF_1.mat';'Base_OM_1.mat';'Base_OF_1.mat';...
'CP_YM_1.mat';'CP_YM_2.mat';'CP_YM_3.mat';'CP_YF_1.mat';'CP_YF_2.mat';'CP
_YF_3.mat';'CP_OM_1.mat';'CP_OF_1.mat';...
'Pilot_Cipro_1.mat';'Pilot_OM_1.mat'};

ExpNames = {...
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'Base_YM_1';'Base_YF_1';'Base_OM_1';'Base_OF_1';...
'CP_YM_1';'CP_YM_2';'CP_YM_3';'CP_YF_1';'CP_YF_2';'CP_YF_3';'CP_OM_1';'CP
_OF_1';...
'Pilot_Cipro_1';'Pilot_OM_1'};
WheelNums =
{'01';'02';'03';'04';'05';'06';'07';'08';'09';'10';'11';'12';'13';'14'};
WheelNames =
{'Wheel_01';'Wheel_02';'Wheel_03';'Wheel_04';'Wheel_05';'Wheel_06';'Wheel
_07';...
'Wheel_08';'Wheel_09';'Wheel_10';'Wheel_11';'Wheel_12';'Wheel_13';'Wheel_
14'};
for i = 1:numel(Files)
load(Files{i});
end

Add the MetaData to the 'wide' data files

DataStruct = struct(...
'Base_YM_1',{Base_YM_1,'Base_YM_1_Metadata.csv','Base_YM_1.csv'},...
'Base_YF_1',{Base_YF_1,'Base_YF_1_Metadata.csv','Base_YF_1.csv'},...
'Base_OM_1',{Base_OM_1,'Base_OM_1_Metadata.csv','Base_OM_1.csv'},...
'Base_OF_1',{Base_OF_1,'Base_OF_1_Metadata.csv','Base_OF_1.csv'},...
'CP_YM_1',{CP_YM_1,'CP_YM_1_Metadata.csv','CP_YM_1.csv'},...
'CP_YM_2',{CP_YM_2,'CP_YM_2_Metadata.csv','CP_YM_2.csv'},...
'CP_YM_3',{CP_YM_3,'CP_YM_3_Metadata.csv','CP_YM_3.csv'},...
'CP_YF_1',{CP_YF_1,'CP_YF_1_Metadata.csv','CP_YF_1.csv'},...
'CP_YF_2',{CP_YF_2,'CP_YF_2_Metadata.csv','CP_YF_2.csv'},...
'CP_YF_3',{CP_YF_3,'CP_YF_3_Metadata.csv','CP_YF_3.csv'},...
'CP_OM_1',{CP_OM_1,'CP_OM_1_Metadata.csv','CP_OM_1.csv'},...
'CP_OF_1',{CP_OF_1,'CP_OF_1_Metadata.csv','CP_OF_1.csv'},...
'Pilot_Cipro_1',{Pilot_Cipro_1,'Pilot_Cipro_1_Metadata.csv','Pilot_Cipro_
1.csv'},...
'Pilot_OM_1',{Pilot_OM_1,'Pilot_OM_1_Metadata.csv','Pilot_OM_1.csv'});
NewStruct = DataStruct;
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for i = 1:length(ExpNames)

CurExp = DataStruct(1).(ExpNames{i});
Columns = CurExp.Properties.VariableNames';
opts = detectImportOptions(DataStruct(2).(ExpNames{i}));
opts =
setvartype(opts,{'Experiment';'Cage';'Animal';'DOB';'Age';'Sex';'Cohort';
'Supplier';'Wheel';'Lights'},'categorical');
%opts = setvartype(opts,{'DOB'},'datetime');
%opts = setvartype(opts,'DatetimeType','text');
CurMeta = readtable(DataStruct(2).(ExpNames{i}),opts);
CurMeta.DOB =
datetime(string(CurMeta.DOB),'InputFormat','MM/dd/yyyy','Format','MMM-ddyyyy');

MetaVars = CurMeta.Properties.VariableNames';
Columns(11:24) = {'Wheel_1';'Wheel_2';'Wheel_3';'Wheel_4';...
'Wheel_5';'Wheel_6';'Wheel_7';'Wheel_8';'Wheel_9';'Wheel_10';...
'Wheel_11';'Wheel_12';'Wheel_13';'Wheel_14'};
CurExp.Properties.VariableNames = Columns;
Timeline = CurExp(:,1:10);
W01 =

[Timeline CurExp(:,11)];

W02 =

[Timeline CurExp(:,12)];

W03 =

[Timeline CurExp(:,13)];

W04 =

[Timeline CurExp(:,14)];

W05 =

[Timeline CurExp(:,15)];

W06 =

[Timeline CurExp(:,16)];

W07 =

[Timeline CurExp(:,17)];

W08 =

[Timeline CurExp(:,18)];

W09 =

[Timeline CurExp(:,19)];
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W10 =

[Timeline CurExp(:,20)];

W11 =

[Timeline CurExp(:,21)];

W12 =

[Timeline CurExp(:,22)];

W13 =

[Timeline CurExp(:,23)];

W14 =

[Timeline CurExp(:,24)];

Wheels = {W01,W02,W03,W04,W05,W06,W07,W08,W09,W10,W11,W12,W13,W14}';
for k = 1:14
CurWheel = Wheels{k};
CurWheel.Experiment(:) = CurMeta{k,1};
CurWheel.Cage(:) = CurMeta{k,2};
CurWheel.Animal(:) = CurMeta{k,3};
CurWheel.Age(:) = CurMeta{k,4};
CurWheel.DOB(:) = CurMeta{k,5};
CurWheel.Sex(:) = CurMeta{k,6};
CurWheel.Cohort(:) = CurMeta{k,7};
CurWheel.Supplier(:) = CurMeta{k,8};
CurWheel.Wheel(:) = CurMeta{k,9};
CurWheel.Lights(:) = CurMeta{k,10};
VarNames = CurWheel.Properties.VariableNames';
CurWheel = movevars(CurWheel,[12:21],'Before','DateTime');
CurWheel.Properties.VariableNames(21)={'Counts'};
Wheels{k,2} = CurWheel;
end
FullTable = Wheels{1,2};
for m = 2:14
FullTable = [FullTable;Wheels{m,2}];
end

NewStruct(1).(ExpNames{i}) = FullTable;
clear('FullTable','Wheels','CurWheel','Timeline','CurExp','CurMeta',...
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'W01','W02','W03','W04','W05','W06','W07','W08','W09','W10','W11','W12','
W13','W14');
end
clearvars -except ExpNames NewStruct MetaVars WheelNames WheelNums

Stack all individual tables and save as create 'All_Wheel_Data_With_Meta.mat'

All_Data = [...
NewStruct(1).Base_YM_1;...
NewStruct(1).Base_YF_1;...
NewStruct(1).Base_OM_1;...
NewStruct(1).Base_OF_1;...
NewStruct(1).CP_YM_1;...
NewStruct(1).CP_YM_2;...
NewStruct(1).CP_YM_3;...
NewStruct(1).CP_YF_1;...
NewStruct(1).CP_YF_2;...
NewStruct(1).CP_YF_3;...
NewStruct(1).CP_OM_1;...
NewStruct(1).CP_OF_1;...
NewStruct(1).Pilot_Cipro_1;...
NewStruct(1).Pilot_OM_1];

% save('All_Wheel_Data_With_Meta.mat','All_Data');
clearvars NewStruct

Build The Data Structure from the MegaTable

%Files = {'All_Wheel_Data_With_Meta.mat'};
%{
for i = 1:numel(Files)
load(Files{i});
end
%}
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%load('All_Wheel_Data_With_Meta.mat');

Noise = table();
Noise.Start = 'Sep-10-2018 12:00:00';
Noise.End = 'Sep-10-2018 12:00:00';
Noise.Type = {''};
Lights = table();
Lights.Regular = 'Sep-10-2018 12:00:00';
Lights.Darkness = 'Sep-10-2018 12:00:00';
All_Wheels = table();
WheelInfo = struct(...
'Has_Data',{''},...
'Phase',{''}, ...
'Experiment',{''}, ...
'Animal',{''},...
'Cage',{''},...
'DOB',{''},...
'Age',{''},...
'Sex',{''},...
'Cohort',{''},...
'Supplier',{''},...
'LightSchedule',{''},...
'Lights',{Lights},...
'RawData',{table()},...
'Noise',{Noise},...
'CleanData',{table()},...
'Notes',{''});
WheelStructure = struct(...
'Wheel_01',WheelInfo,...
'Wheel_02',WheelInfo,...
'Wheel_03',WheelInfo,...
'Wheel_04',WheelInfo,...
'Wheel_05',WheelInfo,...
'Wheel_06',WheelInfo,...
'Wheel_07',WheelInfo,...
'Wheel_08',WheelInfo,...
'Wheel_09',WheelInfo,...
'Wheel_10',WheelInfo,...
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'Wheel_11',WheelInfo,...
'Wheel_12',WheelInfo,...
'Wheel_13',WheelInfo,...
'Wheel_14',WheelInfo,...
'All_Wheels',All_Wheels);
Pilot = struct(...
'Cipro',WheelStructure,...
'Old_Male',WheelStructure);
Baseline = struct(...
'Young_Male',WheelStructure,...
'Old_Male',WheelStructure,...
'Young_Female',WheelStructure,...
'Old_Female',WheelStructure);
CP = struct(...
'YM_1',WheelStructure,...
'YM_2',WheelStructure,...
'YM_3',WheelStructure,...
'YF_1',WheelStructure,...
'YF_2',WheelStructure,...
'YF_3',WheelStructure,...
'OM_1',WheelStructure,...
'OF_1',WheelStructure);
Circadian_Study =
struct('Pilot',Pilot,'Baseline',Baseline,'CP',CP,'All_Data',All_Data);

Load each experiment from All_Data into the structure

Columns = All_Data.Properties.VariableNames';
ExpTitles = unique(All_Data.Experiment);
for i = 1:numel(ExpNames)
CurTable = All_Data(All_Data.Experiment==ExpNames(i),:);
if contains(ExpNames(i),"Base_YM_1")==1
Circadian_Study.Baseline.Young_Male.All_Wheels = CurTable;
else
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end
if

contains(ExpNames(i),"Base_OM_1")==1
Circadian_Study.Baseline.Old_Male.All_Wheels = CurTable;

else
end
if contains(ExpNames(i),"Base_YF_1")==1
Circadian_Study.Baseline.Young_Female.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"Base_OF_1")==1
Circadian_Study.Baseline.Old_Female.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YM_1")==1
Circadian_Study.CP.YM_1.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YM_2")==1
Circadian_Study.CP.YM_2.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YM_3")==1
Circadian_Study.CP.YM_3.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YF_1")==1
Circadian_Study.CP.YF_1.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YF_2")==1
Circadian_Study.CP.YF_2.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_YF_3")==1
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Circadian_Study.CP.YF_3.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_OM_1")==1
Circadian_Study.CP.OM_1.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"CP_OF_1")==1
Circadian_Study.CP.OF_1.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"Pilot_Cipro_1")==1
Circadian_Study.Pilot.Cipro.All_Wheels = CurTable;
else
end
if contains(ExpNames(i),"Pilot_OM_1")==1
Circadian_Study.Pilot.Old_Male.All_Wheels = CurTable;
else
end

end
%}

Load each Wheel's RawData into the structure

for i = 1:numel(WheelNames)
Circadian_Study.Baseline.Young_Male.(WheelNames{i}).RawData = ...
Circadian_Study.Baseline.Young_Male.All_Wheels(Circadian_Study.Baseline.Y
oung_Male.All_Wheels.Wheel==WheelNums(i),:);
Circadian_Study.Baseline.Old_Male.(WheelNames{i}).RawData = ...
Circadian_Study.Baseline.Old_Male.All_Wheels(Circadian_Study.Baseline.Old
_Male.All_Wheels.Wheel==WheelNums(i),:);
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Circadian_Study.Baseline.Young_Female.(WheelNames{i}).RawData = ...
Circadian_Study.Baseline.Young_Female.All_Wheels(Circadian_Study.Baseline
.Young_Female.All_Wheels.Wheel==WheelNums(i),:);
Circadian_Study.Baseline.Old_Female.(WheelNames{i}).RawData = ...
Circadian_Study.Baseline.Old_Female.All_Wheels(Circadian_Study.Baseline.O
ld_Female.All_Wheels.Wheel==WheelNums(i),:);

Circadian_Study.CP.YM_1.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YM_1.All_Wheels(Circadian_Study.CP.YM_1.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.YM_2.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YM_2.All_Wheels(Circadian_Study.CP.YM_2.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.YM_3.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YM_3.All_Wheels(Circadian_Study.CP.YM_3.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.YF_1.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YF_1.All_Wheels(Circadian_Study.CP.YF_1.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.YF_2.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YF_2.All_Wheels(Circadian_Study.CP.YF_2.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.YF_3.(WheelNames{i}).RawData = ...
Circadian_Study.CP.YF_3.All_Wheels(Circadian_Study.CP.YF_3.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.OM_1.(WheelNames{i}).RawData = ...
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Circadian_Study.CP.OM_1.All_Wheels(Circadian_Study.CP.OM_1.All_Wheels.Whe
el==WheelNums(i),:);
Circadian_Study.CP.OF_1.(WheelNames{i}).RawData = ...
Circadian_Study.CP.OF_1.All_Wheels(Circadian_Study.CP.OF_1.All_Wheels.Whe
el==WheelNums(i),:);

Circadian_Study.Pilot.Cipro.(WheelNames{i}).RawData = ...
Circadian_Study.Pilot.Cipro.All_Wheels(Circadian_Study.Pilot.Cipro.All_Wh
eels.Wheel==WheelNums(i),:);
Circadian_Study.Pilot.Old_Male.(WheelNames{i}).RawData = ...
Circadian_Study.Pilot.Old_Male.All_Wheels(Circadian_Study.Pilot.Old_Male.
All_Wheels.Wheel==WheelNums(i),:);
end
%}

Load the MetaData from each Wheel's RawData into the structure

Phases = {'Baseline';'CP';'Pilot'};
FieldOrder = { ...
'Phase'; ...
'Experiment'; ...
'Wheel_Number'; ...
'Has_Data'; ...
'Animal'; ...
'DOB'; ...
'Age'; ...
'Sex'; ...
'Cage'; ...
'Cohort'; ...
'Supplier'; ...
'LightSchedule';...
'Lights'; ...
'RawData'; ...
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'Noise'; ...
'CleanData'; ...
'Notes'};
for g = 1:numel(Phases)
if g==1
MetaDataLocs =
{'Young_Male';'Old_Male';'Young_Female';'Old_Female'};
elseif g==2
MetaDataLocs =
{'YM_1';'YM_2';'YM_3';'YF_1';'YF_2';'YF_3';'OM_1';'OF_1'};
elseif g==3
MetaDataLocs = {'Cipro';'Old_Male'};
end
for h = 1:numel(MetaDataLocs)
for i = 1:numel(WheelNames)

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Wheel_Numbe
r = ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Wheel(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Phase = ...
Phases{g};

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Experiment
= ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Experiment(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Animal =
...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
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a.Animal(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Has_Data =
...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Animal(1));
if
Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Has_Data=="
NaN"
Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Has_Data=fa
lse;
else
Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Has_Data=tr
ue;
end

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Cage = ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Cage(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).DOB = ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.DOB(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Age = ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Age(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Sex = ...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
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a.Sex(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Cohort =
...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Cohort(1));

Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).Supplier =
...
char(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i}).RawDat
a.Supplier(1));
Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i})
= ...
orderfields(Circadian_Study.(Phases{g}).(MetaDataLocs{h}).(WheelNames{i})
,FieldOrder);

end
end
end
clearvars -except All_Data Circadian_Study ExpNames;

Step 3 - Add Light Schedule
% Clear All Current Variables and Console
%
clear all;
close all;
clc
%}
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format long;

Load Files (VERY LARGE - TAKES TIME)

Files = {...
'All_Data_After_Step_2.mat';...
'Circadian_Study_Database_After_Step_2.mat'};

ExpNames = string({...
'Base_YM_1';'Base_YF_1';'Base_OM_1';'Base_OF_1';...
'CP_YM_1';'CP_YM_2';'CP_YM_3';'CP_YF_1';'CP_YF_2';'CP_YF_3';'CP_OM_1';'CP
_OF_1';...
'Pilot_Cipro_1';'Pilot_OM_1'});
ExpNames = sortrows(ExpNames);
WheelNums =
{'01';'02';'03';'04';'05';'06';'07';'08';'09';'10';'11';'12';'13';'14'};
WheelNames =
{'Wheel_01';'Wheel_02';'Wheel_03';'Wheel_04';'Wheel_05';'Wheel_06';'Wheel
_07';...
'Wheel_08';'Wheel_09';'Wheel_10';'Wheel_11';'Wheel_12';'Wheel_13';'Wheel_
14'};
for i = 1:numel(Files)
load(Files{i});
end

Work on One Table At A Time

CurData = All_Data;
%CurData = Circadian_Study.Baseline.Young_Male.All_Wheels;
%CurData = Circadian_Study.Baseline.Old_Male.All_Wheels;
clearvars Circadian_Study All_Data
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CurData_ColumnProperties(:,1) = CurData.Properties.VariableNames;
CurData_ColumnProperties(:,2) =
varfun(@class,CurData,'OutputFormat','cell');

%SideBySide = {};

Change the Column Varible Types to Strings from Categorical

%{
for i = 1:10
CurData.(i) = string(table2array(CurData(:,i)));
end
CurData_ColumnProperties(:,2) =
varfun(@class,CurData,'OutputFormat','cell');
%{
for i = 1:13
CurData.(i) = categorical(table2array(CurData(:,i)));
end
%}
%}

Experimental Constants

fs = 1/60; % Sample rate, which is set in ClockLab (1 minute = 1/60sec)
MinutesInDay = 1440;
LightsOffHr = 8; % Input the time that lights turn off
LightsOnHr = 20; % Input the time that lights turn on
LightsOffMinute = LightsOffHr * 60; % This corresponds to 8:00am
LightsOnMinute = LightsOnHr * 60; % This corresponds to 8:00pm

Add HasData,Lights,LightSchedule Columns

% Determine if a Wheel Record Contains Data
%RowHasData = categorical(1:height(CurData),1)';
CurData.HasData(:) = "1";
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CurData = movevars(CurData,'HasData','Before',1);
CurData.HasData(CurData.Cage=="NaN") = "0";
CurData.HasData(CurData.Animal=="0000") = "0"; % OM Wheel 13 - Didn't run
/ no signal
CurData.HasData(CurData.Animal=="0040") = "0"; % YM Wheel 06 - SUPER
noisy

ExpLightSchedule = {};
for i = 1:length(ExpNames)
ExpLightSchedule{i,1} = string(ExpNames{i});
ExpLightSchedule{i,2} =
string(min(table2array(CurData(CurData.Experiment==ExpNames(i),'DateTime'
))));
ExpLightSchedule{i,3} =
string(max(table2array(CurData(CurData.Experiment==ExpNames(i),'DateTime'
))));
end
% This looks very good now that every experiment begins and ends at
20:00:00
% Converts the ExpLightSchedule to a table, and renames the variables
ExpLightSchedule =
table(ExpLightSchedule(:,1),ExpLightSchedule(:,2),ExpLightSchedule(:,3));
ExpLightSchedule.Properties.VariableNames =
{'Experiment';'Time_Start_Exp';'Time_End_Exp'};

load('ExpDarkness3.mat');

% have to make sure that the ExpLightSchedule experiment names are in the
% same order as the ExpDarkness experiment names *****************
% ADDITIONALLY, I NEEDED TO MAKE SURE THAT THE ExpNames LIST WAS ALSO
% SORTED SO THAT A LATER PIECE OF CODE WHICH APPLIES THE 00:24 12:12
VALUES
% WORKS PROPERLY
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ExpLightSchedule.Experiment = string(ExpLightSchedule.Experiment);
ExpLightSchedule = sortrows(ExpLightSchedule,1);
ExpDarkness = sortrows(ExpDarkness,1);
% Not really sure why that was necessary, but I ensured everything was
% sorted correctly before proceeding on 2/6/2020

ExpLightSchedule.Time_Start_Darkness = ExpDarkness(:,2);
ExpLightSchedule.Time_End_Darkness = ExpDarkness(:,3);
% save('ExpLightSchedule_New.mat','ExpLightSchedule'); % This was created
on 2/6/2020
% This initially sets ALL experiments to the default reverse light cycle
CurData.LightSchedule = CurData.Lights;
CurData.LightSchedule(:) = '12:12';
CurData =
movevars(CurData,{'LightSchedule';'Lights'},'Before','DateTime');
% Extract Light and Dark Rows
RowsDark = CurData.ClockHourBin>=LightsOffHr &
CurData.ClockHourBin<LightsOnHr;
RowsLight = CurData.ClockHourBin<LightsOffHr |
CurData.ClockHourBin>=LightsOnHr;
% Set .Lights value to binary: 0 = off , 1 = on
CurData.Lights(RowsDark) = 'Off';
CurData.Lights(RowsLight) = 'On';

%ExpDarkness(1:6,2:3) = datetime(ExpDarkness(1:6,2:3),'InputFormat','MMMdd-yyyy HH:mm:ss');
for i = 1:length(ExpNames)
if ~strcmp(ExpDarkness(i,2),"NaN")
CurData.LightSchedule((CurData.Experiment==ExpNames(i))&(CurData.DateTime
>=ExpDarkness(i,2))&(CurData.DateTime<=ExpDarkness(i,3))) = "00:24";
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end
end
CurData.Lights_Normal = CurData.Lights;
CurData = movevars(CurData,{'Lights_Normal'},'After','LightSchedule');
CurData.Lights(CurData.LightSchedule=="00:24")="Off";
% ConstantDarkness = CurData(CurData.LightSchedule=="00:24",:);
All_Data = CurData;
%clearvars -except All_Data ExpNames Circadian_Study
All_Data_ColumnProperties(:,1) = All_Data.Properties.VariableNames;
All_Data_ColumnProperties(:,2) =
varfun(@class,All_Data,'OutputFormat','cell');

Phases = ["Baseline","CP","Pilot"];
All_Data.Phase(:) = "Filler";
All_Data = movevars(All_Data,'Phase','After','HasData');

for g = 1:length(Phases)
if g==1
NewPhase = {'Base_YM_1';'Base_OM_1';'Base_YF_1';'Base_OF_1'};
elseif g==2
NewPhase =
{'CP_YM_1';'CP_YM_2';'CP_YM_3';'CP_YF_1';'CP_YF_2';'CP_YF_3';'CP_OM_1';'C
P_OF_1'};
elseif g==3
NewPhase = {'Pilot_Cipro_1';'Pilot_OM_1'};
end
for i = 1:length(NewPhase)
All_Data.Phase(All_Data.Experiment==NewPhase(i)) = Phases{g};
end
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end

Change Values for Lights On and Off

%All_Data.LightSchedule(All_Data.LightSchedule=="Reverse")= "12:12";
%All_Data.LightSchedule(All_Data.LightSchedule=="Darkness")= "00:24";
%All_Data.Lights_Normal(All_Data.Lights_Normal=="0")= "Off";
%All_Data.Lights_Normal(All_Data.Lights_Normal=="1")= "On";
%All_Data.Lights(All_Data.Lights=="0")= "Off";
%All_Data.Lights(All_Data.Lights=="1")= "On";

Save Output

% save('All_Data_After_Step_3.mat','All_Data'); % This was created on
2/6/2020

Step 4 - Mark Noise and Cleanup Data

% Clear All Current Variables and Console
%
clear all;
close all;
clc
%}
format long;

Load Files (VERY LARGE - TAKES TIME)

Files = {...
'All_Data_After_Step_3.mat'};
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ExpNames = string({...
'Base_YM_1';'Base_YF_1';'Base_OM_1';'Base_OF_1';...
'CP_YM_1';'CP_YM_2';'CP_YM_3';'CP_YF_1';'CP_YF_2';'CP_YF_3';'CP_OM_1';'CP
_OF_1';...
'Pilot_Cipro_1';'Pilot_OM_1'});
ExpNames = sortrows(ExpNames);
WheelNums =
{'01';'02';'03';'04';'05';'06';'07';'08';'09';'10';'11';'12';'13';'14'};
WheelNames =
{'Wheel_01';'Wheel_02';'Wheel_03';'Wheel_04';'Wheel_05';'Wheel_06';'Wheel
_07';...
'Wheel_08';'Wheel_09';'Wheel_10';'Wheel_11';'Wheel_12';'Wheel_13';'Wheel_
14'};
for i = 1:numel(Files)
load(Files{i});
end
All_Data_Columns(:,1) = All_Data.Properties.VariableNames;
All_Data_Columns(:,2) = varfun(@class,All_Data,'OutputFormat','cell');

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%

Data Cleanup (Spurrious Data)

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%
% Moving Average** Filter for Spurrious Data
% Sets noise = average of DAY BEFORE activity (3 point moving average)
%

% CURRENTLY, THIS FILTER IS SET UP TO PASS THROUGH THE DATA TWICE,
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% ACCORDING TO THE LOOP COUNTER 'N', A SECOND PASS WAS NEEDED TO CORRECT
% RESIDUAL BACKGROUND NOISE IN WHEEL 6 OF THE OLD FEMALES. THE UNFILTERED
% FILE USED FOR THIS WAS 'Baseline_Data_Cleaned_9_23_19.mat', AND WAS
SAVED
% AS 'Baseline_Data_Twice_Filtered_9_26
%load('Baseline_Data_Cleaned_9_23_19.mat');
%load('All_Data_BEFORE_NOISE_CLEANUP.mat');
% load('All_Data_Before_Clean_Oct_3.mat') % This was originally
uncommented when I began working on 2-6-2020
%{
load('Noise_Notes4.mat'); % Noise_Notes 4 includes a filter for the one
minute of missing OM data on 10-17-2018
% Create a blank template with unique Experiment and Wheel combinations
so
% that I can go record by record in ClockLab and determine which chunks
of
% time need to be filtered...
Noise_Notes_5 = unique(All_Data(:,{'Experiment';'Wheel'}));
Noise_Notes_5.Experiment = string(Noise_Notes_5.Experiment);
Noise_Notes_5.Wheel = string(Noise_Notes_5.Wheel);
Noise_Notes_5.Noise_Start(:) = "";
Noise_Notes_5.Noise_End(:) = "";
Noise_Notes_5.Noise_Type(:) = "";
% Create a new blank template to manually look at each recording and list
% the times that need to be cleaned
Noise_Notes_6 = vertcat(Noise_Notes,Noise_Notes_5);
Injection_Times = Noise_Notes_6;
Noise_Notes_5 = Noise_Notes_6;
%{
TableToWrite = Injection_Times;
FileName = 'Injection_Times_New.csv';
writetable(TableToWrite,FileName);
%}
%}
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file = 'Noise_Notes_5.csv';

opts = delimitedTextImportOptions('NumVariables',6,...
'VariableNames',{'Experiment','Wheel','Noise_Start','Noise_End','Noise_Ty
pe','Discard_After'},...
'VariableTypes',{'categorical','double','string','string','string','strin
g'},...
'DataLines',[2 inf]);
Noise_Notes_5 = readtable(file,opts);
Noise_Notes_5.Wheel = arrayfun(@(x)
sprintf('%02d',x),Noise_Notes_5.Wheel,'un',0);
Noise_Notes_5.Wheel = categorical(Noise_Notes_5.Wheel);

Noise_Notes_5.Noise_Start =
datetime(Noise_Notes_5.Noise_Start,'InputFormat','MMM-dd-yyyy HH:mm:ss');
Noise_Notes_5.Noise_Start.Format = 'MMM-dd-yyyy HH:mm:ss';
Noise_Notes_5.Noise_End =
datetime(Noise_Notes_5.Noise_End,'InputFormat','MMM-dd-yyyy HH:mm:ss');
Noise_Notes_5.Noise_End.Format = 'MMM-dd-yyyy HH:mm:ss';
Noise_Notes_5.Discard_After =
datetime(Noise_Notes_5.Discard_After,'InputFormat','MMM-dd-yyyy
HH:mm:ss');
Noise_Notes_5.Discard_After.Format = 'MMM-dd-yyyy HH:mm:ss';
% THIS LINE ADJUSTS THE NOISE_NOTES TO MATCH THE CORRECTED TIMES FOR
CP_YF_3
Noise_Notes_5{Noise_Notes_5.Experiment=="CP_YF_3",{'Noise_Start','Noise_E
nd'}} = ...
Noise_Notes_5{Noise_Notes_5.Experiment=="CP_YF_3",{'Noise_Start','Noise_E
nd'}}-hours(1);

Noise_Notes_ColumnProperties(:,1) =
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Noise_Notes_5.Properties.VariableNames;
Noise_Notes_ColumnProperties(:,2) =
varfun(@class,Noise_Notes_5,'OutputFormat','cell');

%Noise_Notes_5 = fillmissing(Noise_Notes_5,'constant',"");

Discard =
unique(Noise_Notes_5(:,{'Experiment';'Wheel';'Discard_After'}));
Discard = Discard(~isnat(Discard.Discard_After),:);

Noise_Notes_5 = Noise_Notes_5(:,1:5);
Noise_Notes_5 = Noise_Notes_5(~isnat(Noise_Notes_5.Noise_Start),:);
%Injection_Times =
unique(Noise_Notes_5(:,{'Experiment';'Discard_After'}));
%Injection_Times = unique(All_Data(:,{'Experiment','Wheel'}));

Add Injection_Times

All_Data.Dose(:) = "NaN";
All_Data.Injection_Number(:) = NaN;
All_Data.Injection_Day(:) = NaN;
All_Data = movevars(All_Data, 'Dose', 'Before', 'DateTime');
All_Data = movevars(All_Data, 'Injection_Number', 'Before', 'DateTime');
All_Data = movevars(All_Data, 'Injection_Day', 'Before', 'DateTime');

file = 'Injection_Times_1.csv';
opts = delimitedTextImportOptions('NumVariables',6,...
'VariableNames',{'Experiment','Wheel','Injection_Number','Injection_DateT
ime','Dose'},...
'VariableTypes',{'categorical','double','double','string','categorical'},
...
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'DataLines',[2 inf]);
Injection_Times = readtable(file,opts);
Injection_Times.Wheel = arrayfun(@(x)
sprintf('%02d',x),Injection_Times.Wheel,'un',0);
Injection_Times.Wheel = categorical(Injection_Times.Wheel);
Injection_Times.Injection_DateTime =
datetime(Injection_Times.Injection_DateTime,'InputFormat','MMM-dd-yyyy
HH:mm:ss');
Injection_Times.Injection_DateTime.Format = 'MMM-dd-yyyy HH:mm:ss';
Injection_Times.Injection_DateTime.Format = 'MMM-dd-yyyy';

Injection_Columns(:,1) = Injection_Times.Properties.VariableNames;
Injection_Columns(:,2) =
varfun(@class,Injection_Times,'OutputFormat','cell');
[All_YMD(:,1) All_YMD(:,2) All_YMD(:,3)] = ymd(All_Data.DateTime);
for i = 1:height(Injection_Times)

% Set the injection day
[Cur_YMD(:,1) Cur_YMD(:,2) Cur_YMD(:,3)] =
ymd(Injection_Times{i,'Injection_DateTime'});
Cur_Locations = All_YMD(:,:) == Cur_YMD(1,:);
Cur_Index = double(Cur_Locations);
Cur_Index(:,4) = Cur_Index(:,1)+Cur_Index(:,2)+Cur_Index(:,3);
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Cur_Index(:,4)==3),'Injection_Day'} = 0;
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Cur_Index(:,4)==3),'Dose'} = Injection_Times{i,'Dose'};
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
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All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Cur_Index(:,4)==3),'Injection_Number'} = ...
Injection_Times{i,'Injection_Number'};
if Injection_Times{i,'Experiment'}=="CP_YM_3" ||...
Injection_Times{i,'Experiment'}=="CP_YF_3" ||...
Injection_Times{i,'Experiment'}=="CP_OM_1" ||...
Injection_Times{i,'Experiment'}=="CP_OF_1"
% Set the PRE-injection day **** NOTE THIS WILL NOT WORK IF
INJECTIONS
% WERE MADE ON SEQUENTIAL DAYS
[Pre_YMD(:,1) Pre_YMD(:,2) Pre_YMD(:,3)] =
ymd((Injection_Times{i,'Injection_DateTime'})-days(1));
Pre_Locations = All_YMD(:,:) == Pre_YMD(1,:);
Pre_Index = double(Pre_Locations);
Pre_Index(:,4) = Pre_Index(:,1)+Pre_Index(:,2)+Pre_Index(:,3);
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Pre_Index(:,4)==3),'Injection_Day'} = -1; % This signifies one
day BEFORE injection
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Pre_Index(:,4)==3),'Dose'} = Injection_Times{i,'Dose'};
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Pre_Index(:,4)==3),'Injection_Number'} = ...
Injection_Times{i,'Injection_Number'};

% Set the POST-injection day **** NOTE THIS WILL NOT WORK IF
INJECTIONS
% WERE MADE ON SEQUENTIAL DAYS
[Post_YMD(:,1) Post_YMD(:,2) Post_YMD(:,3)] =
ymd((Injection_Times{i,'Injection_DateTime'})+days(1));
Post_Locations = All_YMD(:,:) == Post_YMD(1,:);
Post_Index = double(Post_Locations);
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Post_Index(:,4) = Post_Index(:,1)+Post_Index(:,2)+Post_Index(:,3);
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Post_Index(:,4)==3),'Injection_Day'} = 1; % This signifies one
day AFTER injection
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Post_Index(:,4)==3),'Dose'} = Injection_Times{i,'Dose'};
All_Data{((All_Data.Experiment == Injection_Times{i,'Experiment'}
&...
All_Data.Wheel == Injection_Times{i,'Wheel'}) &...
Post_Index(:,4)==3),'Injection_Number'} = ...
Injection_Times{i,'Injection_Number'};
else
end
end

%Low_Dose = All_Data(All_Data.Dose=="0.001",:);
%Low_Dose = sortrows(Low_Dose,'DateTime');
%unique(Low_Dose(:,{'Experiment','Wheel'}));

Discard Data

Only_Data = All_Data(All_Data.HasData=="1",:);
No_Data = All_Data(All_Data.HasData=="0",:);
for i = 1:height(Discard)
All_Data{(All_Data.Experiment == Discard{i,'Experiment'} &...
All_Data.Wheel == Discard{i,'Wheel'}) &...
All_Data.DateTime >= Discard{i,'Discard_After'},'HasData'} = "0";
end
No_Data_After = All_Data(All_Data.HasData=="0",:);
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All_Data = All_Data(All_Data.HasData=="1",:);

Try with the whole data set...

WorkingData = All_Data;
%WorkingData = All_Data(All_Data.Experiment=="CP_YM_3",:);
%WorkingData = All_Data(All_Data.HasData=="1",:);
Noise_Notes = Noise_Notes_5;

WorkingData.Counts_Cleaned = WorkingData.Counts;
DataHeight = length(WorkingData.Counts);
Noise_Height = height(Noise_Notes);
%TemporaryData = [WorkingData.Counts_Cleaned,double(WorkingData.Wheel)];
NoisyFiles = unique(Noise_Notes(:,{'Experiment';'Wheel'}));
Errors=table();
Errors2=table();
Errors3=table();

for i = 1:height(NoisyFiles)
FilterSet =
WorkingData((WorkingData.Experiment==NoisyFiles{i,'Experiment'} &
WorkingData.Wheel==NoisyFiles{i,'Wheel'}),{'Experiment';'Wheel';'DateTime
';'Counts'});
FilterSet.Counts_Cleaned(:) = NaN;
FilterSet.Has_Noise(:) = logical(false);
FilterSet.Plus_2(:) = NaN;
FilterSet.Minus_2(:) = NaN;
FilterSet.Plus_1(:) = NaN;
FilterSet.Minus_1(:) = NaN;
FilterHeight = height(FilterSet);
CurNoise =
Noise_Notes(Noise_Notes.Experiment==NoisyFiles{i,'Experiment'}&
Noise_Notes.Wheel==NoisyFiles{i,'Wheel'},:);
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if height(FilterSet)>0
for j = 1:height(CurNoise)

FilterSet.Has_Noise(FilterSet.DateTime>=CurNoise.Noise_Start(j) &
FilterSet.DateTime<=CurNoise.Noise_End(j)) = 1;
end
N = 1;

while N <= 2

for k = 1:height(FilterSet)
if FilterSet.Has_Noise(k)>0
% Check +2 days
if ((k+2880<=FilterHeight) &&
FilterSet.Has_Noise(k+2880)==0 && isnan(FilterSet.Counts(k+2880))==0)==1
FilterSet.Plus_2(k) = FilterSet.Counts(k+2880);
end
% Check -2 days
if ((k-2880>0) && FilterSet.Has_Noise(k-2880)==0 &&
isnan(FilterSet.Counts(k-2880))==0)==1
FilterSet.Minus_2(k) = FilterSet.Counts(k-2880);
end
% Check +1 days
if ((k+1440<=FilterHeight) &&
FilterSet.Has_Noise(k+1440)==0 && isnan(FilterSet.Counts(k+1440))==0)==1
FilterSet.Plus_1(k) = FilterSet.Counts(k+1440);
end
% Check -1 days
if ((k-1440>0) && FilterSet.Has_Noise(k-1440)==0 &&
isnan(FilterSet.Counts(k-1440))==0)==1
FilterSet.Minus_1(k) = FilterSet.Counts(k-1440);
end
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FilterValues = table2array(FilterSet(k,[7 8 9 10]));
FilterLocs = find(~isnan(FilterValues));
FilterSize = length(FilterLocs);

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Weighting factors to favor the day before or after
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% NOTE - THIS MAY NEED TO BE MODIFIED IF TWO DAY 2
VALUES ARE
% COMBINED WITH A SINGLE DAY 1 VALUE
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
if (any(~isnan(FilterValues([1 2])))==1 &
any(isnan(FilterValues([3 4])))==1)==1
FilterValues([1 2]) = FilterValues([1 2])*0.5;
FilterValues([3 4]) = FilterValues([3 4])*1.5;
end
if FilterSize>0
FilterSet.Counts_Cleaned(k) =
(sum(FilterValues(FilterLocs)))/FilterSize;
% What is this shit????
%{
if (CurNoise.Experiment(1)=="Base_OF_1" &
CurNoise.Wheel(1)=="06")==1
FilterSet.Has_Noise(FilterSet.Has_Noise==1) = 1;
else
FilterSet.Has_Noise(k) = FilterSet.Has_Noise(k)1;
end
%}
else
if N==1
Errors = [Errors;FilterSet(k,:)];
else
end
if N==2
Errors2 = [Errors2;FilterSet(k,:)];
else
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end
if N==3
Errors3 = [Errors3;FilterSet(k,:)];
else
end
end
else
%FilterSet.Counts_Cleaned(k) = FilterSet.Counts(k);
end
end
N=N+1;
end
FilterSet.Counts_Cleaned(isnan(FilterSet.Counts_Cleaned)) =
FilterSet.Counts(isnan(FilterSet.Counts_Cleaned));
WorkingData.Counts_Cleaned((WorkingData.Experiment==NoisyFiles{i,'Experim
ent'} & WorkingData.Wheel==NoisyFiles{i,'Wheel'})) =
FilterSet.Counts_Cleaned;
else
end
end
%All_Data = WorkingData;

%{
%{

%{
figure(12)
hold on;
Sub1 = subplot(3,1,1);
P1 = plot(WorkingData.Counts);
P1(1).Color = [0 0 0 1];
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Sub2 = subplot(3,1,2)
P2 = plot(WorkingData.Counts_Cleaned);
P2(1).Color = [0 1 0 1];
Sub3 = subplot(3,1,3)
P3 = plot([WorkingData.Counts, WorkingData.Counts_Cleaned]);
P3(1).Color = [0 0 0 1];
P3(2).Color = [0 1 0 1];
hold off;
linkaxes([Sub1,Sub2,Sub3],'xy');

plot(WorkingData.DateTime,[WorkingData.Counts
WorkingData.Counts_Cleaned]);
plot(WorkingData.DateTime,[WorkingData.Counts_Cleaned]);

Baseline_Data = WorkingData;

%}
%}
LessTen = WorkingData(WorkingData.ZTDayBin<=10,:);
WorkingData = All_Data;
%}

Step 5 - Select and Splice Data
clear all
close all
clc
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load('All_Data_After_Step_4.mat');
Baseline_Data = All_Data(All_Data.Phase=="Baseline",:);
clearvars All_Data
ExpNames = string({...
'Base_YM_1';'Base_OM_1';'Base_YF_1';'Base_OF_1'});
%ExpNames = sortrows(ExpNames);
TimeScale = 1440;
if TimeScale == 1440
TimeVariable = 'ZTMinuteBin';
elseif TimeScale == 24
TimeVariable = 'ZTHourBin';
end
% This section removes the single timepoint at the end of each experiment
for i = 1:length(ExpNames)
LastDay =
round(max(Baseline_Data.ZTDay(Baseline_Data.Experiment==ExpNames(i))));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDay=
=LastDay),:) = [];
end
%{
% This section removes the entire LAST ZTDayBin
for i = 1:length(ExpNames)
LastDay =
max(Baseline_Data.ZTDayBin(Baseline_Data.Experiment==ExpNames(i)));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDayB
in==LastDay),:) = [];
end
% This section removes the entire FIRST ZTDayBin
for i = 1:length(ExpNames)
FirstDay =
min(Baseline_Data.ZTDayBin(Baseline_Data.Experiment==ExpNames(i)));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDayB
in==FirstDay),:) = [];
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end
%}
Start_12_12 = 1;
End_12_12 = 8; %this value is used with a '<' sign
Start_0_24 = 8; %this value is used with a '<=' sign
NumberOfDarkDays = 9;
%Baseline_Data = Baseline_Data(Baseline_Data.ZTDay>=1,:);
Data_LD = Baseline_Data(Baseline_Data.LightSchedule=="12:12",:);

The sorting issue stems from not including NaN's at the end of the ReverseData

Data_LD = Data_LD(Data_LD.ZTDay>=Start_12_12,:);
Data_LD = Data_LD(Data_LD.ZTDay<End_12_12,:);
Data_LD = sortrows(Data_LD,'Animal','ascend');
%ReverseData = ReverseData((ReverseData.ZTDay>=Start_12_12) &
(ReverseData.ZTDay<End_12_12),:);
Data_DD = Baseline_Data(Baseline_Data.LightSchedule=="00:24",:);
Data_DD = sortrows(Data_DD,'Animal','ascend');

YM_Dark = Data_DD(Data_DD.Experiment=="Base_YM_1",:);
YM_Dark_Days = unique(YM_Dark.ZTDayBin);
YM_Dark_Days(:,2) = 1:1:length(YM_Dark_Days);
YM_Dark = YM_Dark(YM_Dark.ZTDayBin<=(YM_Dark_Days(NumberOfDarkDays)),:);
for i = 1:length(YM_Dark_Days)
YM_Dark{YM_Dark.ZTDayBin==YM_Dark_Days(i,1),'ZTDayBin'}=YM_Dark_Days(i,2)
;
end
OM_Dark = Data_DD(Data_DD.Experiment=="Base_OM_1",:);
OM_Dark_Days = unique(OM_Dark.ZTDayBin);
OM_Dark_Days(:,2) = 1:1:length(OM_Dark_Days);
OM_Dark = OM_Dark(OM_Dark.ZTDayBin<=(OM_Dark_Days(NumberOfDarkDays)),:);

178

for i = 1:length(OM_Dark_Days)
OM_Dark{OM_Dark.ZTDayBin==OM_Dark_Days(i),'ZTDayBin'}=OM_Dark_Days(i,2);
end
YF_Dark = Data_DD(Data_DD.Experiment=="Base_YF_1",:);
YF_Dark_Days = unique(YF_Dark.ZTDayBin);
YF_Dark_Days(:,2) = 1:1:length(YF_Dark_Days);
YF_Dark = YF_Dark(YF_Dark.ZTDayBin<=(YF_Dark_Days(NumberOfDarkDays)),:);
for i = 1:length(YF_Dark_Days)
YF_Dark{YF_Dark.ZTDayBin==YF_Dark_Days(i),'ZTDayBin'}=YF_Dark_Days(i,2);
end
OF_Dark = Data_DD(Data_DD.Experiment=="Base_OF_1",:);
OF_Dark_Days = unique(OF_Dark.ZTDayBin);
OF_Dark_Days(:,2) = 1:1:length(OF_Dark_Days);
OF_Dark = OF_Dark(OF_Dark.ZTDayBin<=(OF_Dark_Days(NumberOfDarkDays)),:);
for i = 1:length(OF_Dark_Days)
OF_Dark{OF_Dark.ZTDayBin==OF_Dark_Days(i),'ZTDayBin'}=OF_Dark_Days(i,2);
end
DarknessData_09Days = [YM_Dark;OM_Dark;YF_Dark;OF_Dark];
DarknessData_09Days.ZTDayBin = DarknessData_09Days.ZTDayBin+(End_12_12Start_12_12);
Fused_Light_Dark_Days = [Data_LD;DarknessData_09Days];
Fused_Light_Dark_Days.ZTDayMinuteBin =
Fused_Light_Dark_Days.ZTDayBin+(Fused_Light_Dark_Days.ZTMinuteBin/1440);
Fused_Light_Dark_Days.ZTDayHourBin =
Fused_Light_Dark_Days.ZTDayBin+(Fused_Light_Dark_Days.ZTHourBin/24);
%Fused_YM =
Fused_Light_Dark_Days(Fused_Light_Dark_Days.Experiment=="Base_YM_1",:);
%Fused_YM_0035 = Fused_YM(Fused_YM.Animal=="0035",:);
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Step 6 - Create Surface Plots
clear all
close all
clc
%load('All_Data_After_Step_4.mat');
%load('Fused_Light_Dark_Days_Feb_26.mat');
%load('Fused_Light_Dark_Days_March_25_7LD_7DD.mat');
% for baseline
load('Fused_Light_Dark_Days_March_25_7LD_7DD.mat');
All_Data = Fused_Light_Dark_Days;
clearvars Fused_Light_Dark_Days
ExpNames = string({...
'Base_YM_1';'Base_OM_1';'Base_YF_1';'Base_OF_1'});
WheelNums = string({...
'01';'02';'03';'04';'05';'06';'08';'09';'10';'11';'12';'13';'14'});

% for the chronobiotic records
%load('A:\Data_Analysis\Data\Input\MATLAB_Step_4_Mark_Noise_Info_Clean\Al
l_Data_After_Step_4.mat')
%All_Data = All_Data(All_Data.Phase=="CP",:);

Moving Mean on each wheel of each experiment

movmean_window = 10;
All_Data.Mov_Mean = All_Data.Counts_Cleaned;
i=1;
k=1;
for i = 1:length(ExpNames)
for k = 1:length(WheelNums)
Cur_Wheel_Name = strcat('Wheel_',WheelNums(k));

180

if numel(All_Data((All_Data.Experiment==ExpNames(i) &
All_Data.Wheel==WheelNums(k)),:)) ~= 0

% Replace the mean_Counts_Cleaned column with a moving mean
average
All_Data.Mov_Mean((All_Data.Experiment==ExpNames(i) &
All_Data.Wheel==WheelNums(k))) = ...
movmean(All_Data.Mov_Mean((All_Data.Experiment==ExpNames(i) &
All_Data.Wheel==WheelNums(k))), movmean_window);

end
end
end
All_Data.Counts_Cleaned = All_Data.Mov_Mean;
All_Data.Mov_Mean = [];

If using normalized data to show 'percentage of daily activity'

%load('Baseline_Normalized_Percent_Daily_Counts.mat');
%All_Data = Data_Normalized;

Calculate Average Activity of the Groups

clearvars Data_Normalized Fused_Light_Dark_Days
Baseline_Data = All_Data(All_Data.Phase=="Baseline",:);
clearvars All_Data Fused_Light_Dark_Days
ExpNames = string({...
'Base_YM_1';'Base_OM_1';'Base_YF_1';'Base_OF_1'});
%ExpNames = sortrows(ExpNames);
TimeScale = 1440;
if TimeScale == 1440
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TimeVariable = 'ZTMinuteBin';
elseif TimeScale == 24
TimeVariable = 'ZTHourBin';
end
Early_Risers = 0;
%{
% This section removes the single timepoint at the end of each experiment
for i = 1:length(ExpNames)
LastDay =
round(max(Baseline_Data.ZTDay(Baseline_Data.Experiment==ExpNames(i))));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDay=
=LastDay),:) = [];
end
%}
LD_DD = unique(Baseline_Data(:,{'LightSchedule';'ZTDayBin'}));
% This section removes the entire LAST ZTDayBin
% On 3-25-2020 I ran this section twice using the file
% 'Fused_Light_Dark_Days_Feb_26.mat' to produce a file containing 7 days
of
% LD and 7 days of DD, this new file is saved as both .csv and .mat,
% The csv is 'Fused_Light_Dark_Days_March_25_7LD_7DD.csv'
% The .mat is 'Fused_Light_Dark_Days_March_25_7LD_7DD.mat'
%{
% Fused_Light_Dark_Days = Baseline_Data;
% LD_DD_Sevens =
unique(Fused_Light_Dark_Days(:,{'LightSchedule';'ZTDayBin'}));
%
writetable(Fused_Light_Dark_Days,'Fused_Light_Dark_Days_March_25.csv','De
limiter',',');
%}
%{
i=1;
for i = 1:length(ExpNames)
LastDay =
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max(Baseline_Data.ZTDayBin(Baseline_Data.Experiment==ExpNames(i)));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDayB
in==LastDay),:) = [];
end
LD_DD = unique(Baseline_Data(:,{'LightSchedule';'ZTDayBin'}));
%}
%{
k=1;
while k<=3 %This is a counter to remove the first 3 days
% This section removes the entire FIRST ZTDayBin
for i = 1:length(ExpNames)
FirstDay =
min(Baseline_Data.ZTDayBin(Baseline_Data.Experiment==ExpNames(i)));
Baseline_Data((Baseline_Data.Experiment==ExpNames(i)&Baseline_Data.ZTDayB
in==FirstDay),:) = [];
end
k = k+1;
end
%}
GroupingFactors =
{'Experiment','ZTDay','ZTDayBin','ZTHourBin','ZTMinuteBin','LightSchedule
','Lights','Lights_Normal'};
Measurements = {'Counts_Cleaned'};
Stats = {'mean'};
Averages =
grpstats(Baseline_Data,GroupingFactors,Stats,'DataVars',Measurements);
Averages.Properties.VariableNames(Averages.Properties.VariableNames=="mea
n_Counts_Cleaned") = "Counts_Cleaned";
Averages.GroupCount = [];
clearvars Baseline_Data

Normalization of Daily Activity (SLOW)

%{
GroupingFactors = {'Experiment';'ZTDayBin'};
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Measurements = {'Counts_Cleaned'};
Stats = {'sum'};
Table2Norm = Averages;
Norm_StatsTable =
grpstats(Table2Norm,GroupingFactors,Stats,'DataVars',Measurements);
Norm_StatsTableVariables = Norm_StatsTable.Properties.VariableNames;
Norm_StatsTableVariables = strrep(Norm_StatsTableVariables,"sum_","");
Norm_StatsTable.Properties.VariableNames = Norm_StatsTableVariables;
Exp_Names = unique(Norm_StatsTable.Experiment);
ZTDayBins = unique(Norm_StatsTable.ZTDayBin);
Data_Normalized = Table2Norm;
ZTMinuteBin = unique(Data_Normalized.ZTMinuteBin);
Columns_Norm_StatsTable = [Norm_StatsTable.Properties.VariableNames'
varfun(@class,Norm_StatsTable,'OutputFormat','cell')'];
Columns_NormData = [Data_Normalized.Properties.VariableNames'
varfun(@class,Data_Normalized,'OutputFormat','cell')'];
h=1;
i=1;
j=1;
k=2;

for h = 1:length(Measurements)
for i = 1:length(Exp_Names)
for k = 1:length(ZTDayBins)
for m = 1:length(ZTMinuteBin)
Data_Normalized{(Data_Normalized.Experiment ==
Exp_Names(i) & ...
Data_Normalized.ZTDayBin == ZTDayBins(k) & ...
Data_Normalized.ZTMinuteBin == ZTMinuteBin(m)), ...
Measurements(h)} = ...
Data_Normalized{(Data_Normalized.Experiment ==
Exp_Names(i) & ...
Data_Normalized.ZTDayBin == ZTDayBins(k) & ...
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Data_Normalized.ZTMinuteBin == ZTMinuteBin(m)), ...
Measurements(h)} ./
(Norm_StatsTable{(Norm_StatsTable.Experiment == Exp_Names(i) & ...
Norm_StatsTable.ZTDayBin == ZTDayBins(k)),
Measurements(h)})*100;...
end
end
end
end
Averages = Data_Normalized;
%}

Creating the Surface Plots

Plots = struct();
for i = 1:length(ExpNames)
Plots.(ExpNames(i)).Surf_Off = [];
Plots.(ExpNames(i)).Surf_All = [];
Plots.(ExpNames(i)).ax1 = [];
Plots.(ExpNames(i)).ax2 = [];
Plots.(ExpNames(i)).All_Axes = [];
Plots.(ExpNames(i)).AxisLink = [];
end

for j = 1:length(ExpNames)
Cur_Data = Averages(Averages.Experiment==ExpNames(j),...
{'Experiment','ZTDay','ZTDayBin','ZTHourBin','ZTMinuteBin','LightSchedule
','Lights','Lights_Normal','Counts_Cleaned'});
%Cur_Data = Cur_Data(Cur_Data.ZTDay<=5,:);
Exp_Start = min(Cur_Data.ZTDayBin);
Exp_End = max(Cur_Data.ZTDayBin);
Exp_Length = length(unique(Cur_Data.ZTDayBin));
ZTDay = Cur_Data.ZTDay;
ZTDayBin = Cur_Data.ZTDayBin;
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ZTHourBin = Cur_Data.ZTHourBin;
ZTMinuteBin = Cur_Data.ZTMinuteBin;
Counts_Cleaned = Cur_Data.Counts_Cleaned;
LightSchedule = Cur_Data.LightSchedule;
Lights = Cur_Data.Lights;
Lights_Normal = Cur_Data.Lights_Normal;
Lights_On = find(Lights=="On");
Lights_Off = find(Lights=="Off");
Signal = Counts_Cleaned;
Signal_Lights_On = Signal-NaN;
Signal_Lights_On(Lights_On) = Signal(Lights_On);
Signal_Lights_Off = Signal-NaN;
Signal_Lights_Off(Lights_Off) = Signal(Lights_Off);
if Exp_Start>0
Length_Day(1:Exp_Length) = TimeScale;
elseif Exp_Start == 0
Length_Day(1:(Exp_Length+1)) = TimeScale;
end
RR(1:max(ZTDayBin)+1) = TimeScale; % this was functional
%RR = ExpLength;
% Exp_Length = length(Length_Day);
Days_Used = unique(Averages.ZTDayBin);
%Stack=zeros(TimeScale,M)+NaN; %from spiral plot
Stack = zeros(TimeScale,Exp_Length)+NaN;
Stack_Lights_On = Stack;
Stack_Lights_Off = Stack;
for i = 1:Exp_Length
%Stack(:,i) = Signal((Cur_Data.ZTDay>=i & Cur_Data.ZTDay<i+1));
Stack(:,i) = Signal((Cur_Data.ZTDayBin>=Days_Used(i)) &
Cur_Data.ZTDayBin<Days_Used(i)+1); % Note that (i,:) is reversed from
before
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Stack_Lights_On(:,i) =
Signal_Lights_On((Cur_Data.ZTDayBin>=Days_Used(i) &
Cur_Data.ZTDayBin<Days_Used(i)+1)); % Note that (i,:) is reversed from
before
Stack_Lights_Off(:,i) =
Signal_Lights_Off((Cur_Data.ZTDayBin>=Days_Used(i) &
Cur_Data.ZTDayBin<Days_Used(i)+1)); % Note that (i,:) is reversed from
before
end
% Stack_Lights_On = Stack_Lights_On + 0.01;
Stack_Lights_Off = Stack_Lights_Off*0;
%Stack_Lights_On = Stack_Lights_On(Lights_On);
%Stack_Lights_Off = Stack_Lights_Off(Lights_Off);
%ZTDayBin_Lights_On = ZTDayBin_Lights_On(Lights_On);
%ZTDayBin_Lights_Off = ZTDayBin_Lights_Off(Lights_Off);
GraphTitle = ExpNames(j);
GraphTitle = strrep(GraphTitle,"_1","");
GraphTitle = strrep(GraphTitle,"_"," ");
GraphTitle = strrep(GraphTitle,"Base","Baseline");
GraphTitle = strrep(GraphTitle,"Y","Young ");
GraphTitle = strrep(GraphTitle,"O","Old ");
GraphTitle = strrep(GraphTitle,"M","Male");
GraphTitle = strrep(GraphTitle,"F","Female");
%figure('NumberTitle','off','Name',GraphTitle,'Tag',GraphTitle)
if j==1
figure('Position',[0 0 1 1]);
set(gcf, 'Units', 'Normalized', 'OuterPosition', [0 0 1 1]);
set(gcf,'color','white')
end
Plots.(ExpNames(j)).ax1 = subplot(2,2,j);
[X1,Y1] = meshgrid(1:Exp_Length,1:TimeScale);
Plots.(ExpNames(j)).Surf_Off = surf(X1,Y1,Stack_Lights_Off);
hold(Plots.(ExpNames(j)).ax1,'on')
grid on;
Plots.(ExpNames(j)).ax1.ActivePositionProperty = 'position';
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Plots.(ExpNames(j)).Surf_Off.CDataMapping = 'scaled'; %'direct';
Plots.(ExpNames(j)).ax1.Colormap(:) = 0;
shading interp
lighting gouraud
%Plots.(ExpNames(j)).Surf_Off.FaceAlpha = 0.8;
Plots.(ExpNames(j)).Surf_Off.FaceAlpha = 1;
axis off
Cur_Sub_Pos = Plots.(ExpNames(j)).ax1.Position;
Plots.(ExpNames(j)).ax2 = axes('Position',Cur_Sub_Pos);
%Plots.(ExpNames(j)).ax2 = axes;
Plots.(ExpNames(j)).Surf_All = surf(X1,Y1,Stack);
Plots.(ExpNames(j)).Surf_All.CDataMapping = 'scaled'; %'direct';
Plots.(ExpNames(j)).ax2.ActivePositionProperty = 'position';
c = jet;
%c = parula;
Plots.(ExpNames(j)).ax2.Colormap = c;
shading interp
lighting gouraud
%Plots.(ExpNames(j)).Surf_All.FaceAlpha = 0.6;
Plots.(ExpNames(j)).Surf_All.FaceAlpha = 0.8;
%plot3(1:M,qrs(:,1),qrs(:,2)+offset,'go-','MarkerFaceColor','g') %
need to make this plot the daily peaks or something
axis off
title(GraphTitle,'FontName','Gadugi','FontSize',16,'FontWeight','bold');
Plots.(ExpNames(j)).ax1.Visible = 'on';
Plots.(ExpNames(j)).ax2.YLim = [0 TimeScale];
Plots.(ExpNames(j)).ax2.YTick = linspace(0,1440,9);
Plots.(ExpNames(j)).ax2.XLim = [1 Exp_Length];
Plots.(ExpNames(j)).ax2.ZLim = [0 max(Averages.Counts_Cleaned)];
Plots.(ExpNames(j)).ax2.ZLim = [0 100];
Plots.(ExpNames(j)).ax1.ZLim = Plots.(ExpNames(j)).ax2.ZLim;
Plots.(ExpNames(j)).ax1.YLim = Plots.(ExpNames(j)).ax2.YLim;
Plots.(ExpNames(j)).ax1.XLim = Plots.(ExpNames(j)).ax2.XLim;
%}
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Plots.(ExpNames(j)).ax1.View = [80, 45];
Plots.(ExpNames(j)).ax2.View = [80, 45];
%{
Axes = findobj(gcf,'type', 'axes');
%Plots.(ExpNames(j)).All_Axes = Axes;
Plots.(ExpNames(j)).AxisLink =
linkprop(Axes,{'View','XLim','YLim','ZLim'});
%}
%Plots.(ExpNames(j)).AxisLink = linkprop(Axes,{'CameraUpVector',...
%

'CameraPosition','CameraTarget','CameraViewAngle','View'});

% 'CameraViewAngle' % makes the graph small, but appropriately scaled
% 'CameraTarget' % Doesn't do much...
% 'CameraPosition' % Doesn't do much...
% 'CameraUpVector' % Doesn't do much...
%Axes = findobj('type', 'axes');
%Plots.AxisLink = linkprop(Axes,{'View','XLim','YLim','ZLim'});
%setappdata(gcf, 'StoreTheLink', Plots.AxisLink);

%
Plots.(ExpNames(j)).ax1.FontName = 'Arial';
Plots.(ExpNames(j)).ax1.FontWeight = 'bold';
Plots.(ExpNames(j)).ax1.FontSize = 11;

Plots.(ExpNames(j)).ax1.XLabel.String = 'Day of Running';
Plots.(ExpNames(j)).ax1.XLabel.FontName = 'Arial';
Plots.(ExpNames(j)).ax1.XLabel.FontWeight = 'bold';
Plots.(ExpNames(j)).ax1.XLabel.FontSize = 12;
Plots.(ExpNames(j)).ax1.XLabel.Rotation = 300;
Plots.(ExpNames(j)).ax1.XLabel.Position =
Plots.(ExpNames(j)).ax1.XLabel.Position + [0 40 0];

Plots.(ExpNames(j)).ax1.ZLabel.String = ['Average Wheel' newline
'Rotations per Minute (RPM)'];
Plots.(ExpNames(j)).ax1.XLabel.FontName = 'Arial';
Plots.(ExpNames(j)).ax1.XLabel.FontWeight = 'bold';
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Plots.(ExpNames(j)).ax1.XLabel.FontSize = 12;
% Plots.(ExpNames(j)).ax1.ZLabel.Rotation = 0;

if TimeVariable=='ZTMinuteBin'
Plots.(ExpNames(j)).ax1.YLabel.String = 'Zeitgeber Time(Minute of
Day)';
elseif TimeVariable=='ZTHourBin'
Plots.(ExpNames(j)).ax1.YLabel.String = 'Zeitgeber Time(Hour of
Day)';
end
Plots.(ExpNames(j)).ax1.XLabel.FontName = 'Arial';
Plots.(ExpNames(j)).ax1.YTick = linspace(0,1440,9);
Plots.(ExpNames(j)).ax1.YLabel.FontWeight = 'bold';
Plots.(ExpNames(j)).ax1.YLabel.FontSize = 12;
Plots.(ExpNames(j)).ax1.YLabel.Rotation = 2;
Plots.(ExpNames(j)).ax1.YLabel.Position =
Plots.(ExpNames(j)).ax1.YLabel.Position - 2;
end

Axes = findobj('type', 'axes');
Plots.AxisLink = linkprop(Axes,{'View','XLim','YLim','ZLim'});
setappdata(gcf, 'StoreTheLink', Plots.AxisLink);
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